WO2020110154A1 - A chimeric therapeutic vaccine - Google Patents
A chimeric therapeutic vaccine Download PDFInfo
- Publication number
- WO2020110154A1 WO2020110154A1 PCT/IN2019/050877 IN2019050877W WO2020110154A1 WO 2020110154 A1 WO2020110154 A1 WO 2020110154A1 IN 2019050877 W IN2019050877 W IN 2019050877W WO 2020110154 A1 WO2020110154 A1 WO 2020110154A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- egf
- protein
- vaccine composition
- egfl
- Prior art date
Links
- 229940021747 therapeutic vaccine Drugs 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
- 239000002671 adjuvant Substances 0.000 claims abstract description 36
- 230000004083 survival effect Effects 0.000 claims abstract description 34
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims abstract description 26
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 20
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- 210000004027 cell Anatomy 0.000 claims description 96
- 102000037865 fusion proteins Human genes 0.000 claims description 93
- 108020001507 fusion proteins Proteins 0.000 claims description 93
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 229960005486 vaccine Drugs 0.000 claims description 76
- 108010040721 Flagellin Proteins 0.000 claims description 66
- 235000018102 proteins Nutrition 0.000 claims description 59
- 239000013612 plasmid Substances 0.000 claims description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 108010078791 Carrier Proteins Proteins 0.000 claims description 26
- 102000014914 Carrier Proteins Human genes 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 238000003776 cleavage reaction Methods 0.000 claims description 25
- 102100035680 Cadherin EGF LAG seven-pass G-type receptor 2 Human genes 0.000 claims description 23
- 101000715674 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 2 Proteins 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 239000003102 growth factor Substances 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 16
- 238000004255 ion exchange chromatography Methods 0.000 claims description 16
- 238000000746 purification Methods 0.000 claims description 16
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 9
- 229960000723 ampicillin Drugs 0.000 claims description 9
- 239000013613 expression plasmid Substances 0.000 claims description 9
- 210000000987 immune system Anatomy 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 238000001042 affinity chromatography Methods 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 claims description 8
- 230000004614 tumor growth Effects 0.000 claims description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 7
- 102000002689 Toll-like receptor Human genes 0.000 claims description 7
- 108020000411 Toll-like receptor Proteins 0.000 claims description 7
- 239000012266 salt solution Substances 0.000 claims description 7
- 235000019157 thiamine Nutrition 0.000 claims description 7
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- 239000011721 thiamine Substances 0.000 claims description 7
- 239000011573 trace mineral Substances 0.000 claims description 7
- 235000013619 trace mineral Nutrition 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 6
- 230000009465 prokaryotic expression Effects 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- 241001135755 Betaproteobacteria Species 0.000 claims description 5
- 241000588807 Bordetella Species 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 5
- 241000192125 Firmicutes Species 0.000 claims description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- HACHPVCYFLSKSB-UMJDSZQGSA-N ManNAz-DBCO-Pam3CSK4 Chemical compound CCCCCCCCCCCCCCCC(N[C@H](CSCC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C(N[C@H](CO)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(NCCC(N(C1)C2=CC=CC=C2C2N(C(N[C@H]([C@H](C3)O)[C@H]([C@@H]([C@@H](CO)O)O)O[C@@]3(C(O)=O)O)=O)N=NC2C2=C1C=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O HACHPVCYFLSKSB-UMJDSZQGSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims description 3
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 108010073443 Ribi adjuvant Proteins 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 3
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001686 afatinib Drugs 0.000 claims description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 3
- 229940001007 aluminium phosphate Drugs 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 159000000013 aluminium salts Chemical class 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 3
- 229950002205 dacomitinib Drugs 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002751 imiquimod Drugs 0.000 claims description 3
- 210000003000 inclusion body Anatomy 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 3
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 3
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 claims description 3
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims description 3
- 229950000908 nazartinib Drugs 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 229950000778 olmutinib Drugs 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 3
- 241000894007 species Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 89
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 37
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002626 targeted therapy Methods 0.000 abstract description 12
- 230000002622 anti-tumorigenesis Effects 0.000 abstract description 9
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 abstract description 8
- 229940116978 human epidermal growth factor Drugs 0.000 abstract description 8
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000019491 signal transduction Effects 0.000 abstract description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 124
- 101800003838 Epidermal growth factor Proteins 0.000 description 123
- 102400001368 Epidermal growth factor Human genes 0.000 description 123
- 229940116977 epidermal growth factor Drugs 0.000 description 123
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 33
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 238000002255 vaccination Methods 0.000 description 23
- 230000007017 scission Effects 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 19
- 102000001301 EGF receptor Human genes 0.000 description 18
- 108060006698 EGF receptor Proteins 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 17
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 16
- 238000012512 characterization method Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 15
- 238000010276 construction Methods 0.000 description 15
- 238000001262 western blot Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 201000005202 lung cancer Diseases 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 238000012286 ELISA Assay Methods 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 7
- 229920002101 Chitin Polymers 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 7
- 230000000091 immunopotentiator Effects 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000006137 Luria-Bertani broth Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000001024 immunotherapeutic effect Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000012723 sample buffer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 4
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 241001138501 Salmonella enterica Species 0.000 description 4
- GPKUGWDQUVWHIC-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NNC1=CC=C(C=C1)C1=CC=C(NN)C=C1 GPKUGWDQUVWHIC-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000751 protein extraction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- 229940125575 vaccine candidate Drugs 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000045719 human TLR5 Human genes 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 230000017730 intein-mediated protein splicing Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- -1 PDGF Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100024125 Embryonal Fyn-associated substrate Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001053896 Homo sapiens Embryonal Fyn-associated substrate Proteins 0.000 description 1
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101100153381 Homo sapiens TLR5 gene Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108091005686 NOD-like receptors Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101800001978 Ssp dnaB intein Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101150035068 TLR5 gene Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000027540 membrane-bound PRRs Human genes 0.000 description 1
- 108091008872 membrane-bound PRRs Proteins 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to biotechnology, particularly biomedical research or immunotherapy.
- the present disclosure relates to the field of recombinant proteins for use in treating diseases. More specifically, the invention relates to chimeric vaccine comprising human growth hormone sequences and carrier protein encoding the same and methods for expression and using the same as an immunotherapeutic vaccine either alone or in combination with adjuvants to treat Non Small Cell Lung Cancer and other EGF dependant malignant diseases such as breast, bladder, ovarian, vulvia, colon, pulmonary, brain and oesophagus cancers.
- Cancer is a leading cause of deaths worldwide.
- lung cancer is the most common and deadliest cancer causing approximately 1.6 million deaths accounting 19.4% of the total deaths per year, worldwide ( World Health Organization. Lyon, France: International Agency for Research on Cancer; Feb 3, 2014. Press Release No. 224. Available at: http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf).
- lung cancer constitutes 6.9% and 9.3% of cases & deaths respectively from all cancer related deaths in both sexes.
- NSCLC small-cell lung carcinoma
- NSCLC non-small- cell lung carcinoma
- EGFR Epidermal Growth Factor Receptor
- the epidermal growth factor receptor (EGFR) is a transmembrane protein and acts as a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands such as Epidermal Growth Factor (EGF), Transforming Growth Factor (TGF), heparin binding growth factor etc.
- EGF Epidermal Growth Factor
- TGF Transforming Growth Factor
- One of the approaches to reduce, the uncontrolled growth is to reduce the availability of EGF to EGFR, by producing high titer anti-EGF antibodies against autologous huEGF.
- available EGF in serum binds to anti-EGF antibodies raised against EGF based therapeutic vaccine, thereby it decreases the binding of EGF to the receptor (EGFR), which further prevents the cell proliferation.
- EGFR the receptor
- the inherent problem associated with making an anti-EGF based vaccine lies in the fact that it is autologous and present in the human biological system and therefore no anti-EGF antibody (Ab) response is possible.
- EGF based therapeutic vaccine made, which elicits antibodies against EGF, that blocks EGFR, so as to prevent cell growth and to treat lung cancer.
- the said therapeutic vaccine is composed of human recombinant EGF conjugated to P64 carrier protein derived from Neisseria meningitidis and emulsified in Montanide ISA51 (US 2013/0039940 Al; US 2010/0196412 Al).
- EGF based chimeric proteins were generated using recombinant DNA technology, using immunopotentiator, flagellin as a carrier protein, which can not only enables human epidermal growth factor to be recognized by the human immune system, but also can acts as an innate immune modulator after binding to TLR5 (Toll Like Receptor 5), present on the Immune cells.
- TLR5 Toll Like Receptor 5
- TLR5 have been demonstrated to possess anti-cancer properties along with the ability to enhance immune response compared to other TLRs or NLRs or CLRs.
- TLR5 Toll Like Receptor 5
- TLR5 agonists are favourably positioned as potential systemic immunotherapeutic agents because of unusual tissue specificity of expression, uniquely safe profile of induced cytokines, and antitumor efficacy demonstrated in a number of animal models (Li-Fen Lee et al., J Immunol 2000, 164: 2769-2775; Sang Hoon Rhee et al., Gastroenterology 2008, 135:518-528.).
- newer adjuvants in combination with the vaccine antigen may also be desirable.
- Inventors of the present invention describe the use of recombinant chimeric protein of human epidermal growth factor and its vaccine composition with or without adjuvants as a therapeutic vaccine.
- the vaccine has been tested in a mice tumor model and proved that vaccine composition slows down the progression of a tumor, while increasing the survival period for at least 1 week.
- this invention also discloses that the use of vaccine composition, immediately after 1 cycle of TKI (tyrosine kinase inhibitor-based EGFR targeted therapy) treatment, increased survival rate by 30% in tumor induced mice model.
- flagellin tends to impart both adjuvant activity along with anti-tumorigenic activity to the said chimeric protein of recombinant human epidermal growth factor.
- Flagellin is a bigger molecule by itself and chimeric attachment of flagellin to human epidermal growth factor as a single molecule enables the human immune system to recognize EGF as a foreign vaccine antigen and thereby generates anti-EGF antibodies to treat non small cell lung cancer in humans.
- An important objective of this invention is to generate chimeric protein comprising autologous huEGF, so as to produce anti-EGF antibodies against huEGF.
- the object of the present invention is to provide anti-EGF antibodies (antibodies against autologous human growth factor), to make EGF (human growth factor) less available for the EGFR to bind and thereby to prevent cell proliferation.
- Another object of the present invention is to provide more effective methods of vaccine preparation through the use of autologous growth factor by using an effective carrier protein and by increasing the number of copies of growth factor or EGF, by which immune system is able to recognize huEGF as an immunogen and stimulate immune cells to produce anti-EGF antibodies.
- Yet another objective of the invention is to identify new carrier protein which has immunopotentiating property or adjuvant property for the purpose of generating chimeric protein in fusion with human EGF protein.
- One of the objectives of the present invention is to generate chimeric proteins containing EGF and full length or truncated flagellin protein, which function both as a carrier protein & immunopotentiator.
- Another objective is also to increase the anti-EGF antibodies, by increasing the number of EGF copies in chimeric fusion.
- Another objective of the present invention is to evaluate adjuvant and anti-tumorigenic activity of flagellin or fusion proteins containing full length or truncated flagellin.
- Yet another objective of the invention is to provide a vaccine composition with or without adjuvant(s) or any applicable delivery system for prophylaxis and/or therapeutic treatment against non-small cell lung cancer wherein EGF is to be used as a vaccine antigen through chimeric approach with novel immunopotentiators.
- Another objective of the invention is to determine the efficacy of the chimeric protein as a therapeutic vaccine, while increasing the survival rate.
- the present disclosure is directed towards the construction, expression, purification and the characterization of the recombinant chimeric proteins and their respective methods to assess or evaluate the functional properties. Further, the present invention also discloses therapeutic methods of using the recombinant chimeric proteins to treat chronic diseases, such as, for example, lung, breast, head and neck, bladder, prostate, ovarian, vulva, colonic, colorectal, intestinal, pulmonary, brain, oesophagal and other cancers, in which EGF plays an important role to promote cell growth.
- chronic diseases such as, for example, lung, breast, head and neck, bladder, prostate, ovarian, vulva, colonic, colorectal, intestinal, pulmonary, brain, oesophagal and other cancers, in which EGF plays an important role to promote cell growth.
- the recombinant chimeric protein is an immunogenic protein molecule comprising one or more sequences that fold into one physical structure that exposes desired epitopes.
- chimeric protein expressing full length or truncated sequence of a carrier protein and expressing one or more copies or sequences of autologous human epidermal growth factor or alternate self antigens and thereof that induces high titer anti growth factor or anti-EGF antibodies, after being accessible to cells of the immune system.
- growth factors may be selected from human origin and the said sequence can contain functional parts thereof.
- the sequence of human growth factors or the alternate self antigens are codon optimized for better expression in E. coli and they are genetically synthesized.
- the expression of one or more copies or sequence of the growth factor(s) can be present at different positions within the sequence of the recombinant chimeric protein, for example, one copy of growth factor present at N-terminus or C- terminus of the carrier protein and another copy of the growth factor have been positioned at the centre of the flagellin, by replacing the hyper variable regions (D2 & D3), or at N- or C- terminus or in place of D3 region itself.
- D2 & D3 hyper variable regions
- the sequence of the growth factor may include a sequence of one or more of the following growth factors, and/or alternative self-antigens such as, but not limited to, EGF, IGF-1, IGF-2. FGFs 1-23, TGF-a, TGF-b, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EGF, HGF and IFs 1-7.
- the sequence of carrier protein may include full length or truncated flagellin and it is synthetic in origin, either taken from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or y-protcohactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
- the resultant chimeric protein may be a single polypeptide expressing a one or more copies of growth factor or self antigens thereof within the sequence of the carrier protein.
- the sequence of the recombinant protein expresses both huEGF and full length or truncated flagellin and presents the EGF on a surface of the recombinant protein, as it was recognized by the anti-EGF antibodies via western blot technique.
- Further embodiment of the invention describes the method of protein purification comprising cell lysis, denaturation & refolding followed by self-cleavage due to temperature & pH shift, subsequently, further purification techniques such as ion exchange chromatography, size exclusion chromatography or affinity chromatography via chitin binding domain resin or Hydrophobic interaction chromatography or chromatography technique using mixed mode resins etc.
- the further embodiments of the invention also established that the immunogenicity of the chimeric proteins in C57BL/C mice.
- the protein sequences of SEQ IDs 6 to 10 and 16 to 17 containing nucleic acid sequences, SEQ ID Nos. 1 to 5, 11 and 12 are capable to generate anti-EGF antibodies.
- vaccine formulations comprising chimeric proteins with immunomodulator or delivery system have also been made available as one of the embodiments of the present invention optionally in presence of other stabilizers like polyols, sugars such as trehalose or amino acids or combinations.
- a vaccine composition for immunotherapy against cancer comprising:
- a physiologically acceptable buffer selected from phosphate and citrate.
- the vaccine composition of the present invention comprises the vaccine antigen comprising one or more of the chimeric protein sequences as represented by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2).
- the vaccine composition of the present invention comprises chimeric protein as vaccine antigen obtained from a codon optimized gene sequences comprising one or more of as represented by SEQ ID No. 1. (EGFL), SEQ ID No. 2 (E1FS1), SEQ ID No. 3 (E1FS2), SEQ ID No. 4 (E2FS1), SEQ ID No. 5 (E2FS2), SEQ ID No. 11 (BsE2FSl) or SEQ ID No. 12 (EGFL2).
- SEQ ID No. 1. EGFL
- E1FS1 SEQ ID No. 2
- E1FS2 SEQ ID No. 3
- SEQ ID No. 4 E2FS1
- SEQ ID No. 5 E2FS2
- SEQ ID No. 11 BsE2FSl
- SEQ ID No. 12 EGFL2
- the vaccine composition of the present invention comprises chimeric protein as vaccine antigen, which comprises of growth factor linked to N-terminal or C- terminal or middle of the full length or truncated carrier protein and is genetically synthesized.
- the chimeric protein is expressed in prokaryotic expression system through a prokaryotic expression plasmid.
- the growth factor is human EGF.
- the human EGF epitopes are exposed on the surface of the chimeric proteins.
- the composition of the present invention comprises genetically synthesized full length Flagellin protein as carrier protein.
- the carrier protein in the vaccine composition of the present invention is a genetically synthesized truncated Flagellin protein without the hypervariable region which are from amino acid numberl78 to amino acid number 405.
- the genetically synthesized sequence is selected from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g— protcobactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
- the carrier protein the vaccine composition of the present invention helps the immune system to recognize autologous EGF to induce immune response against EGF and acts as adjuvant to enhance Th2 responses or B cell mediated immune responses.
- the adjuvant present in the composition of the invention is selected from one or more of a group of aluminium salt such as aluminium phosphate or aluminium hydroxide, squalene based adjuvants such as MF59, montanide, RIBI adjuvant, incomplete Freund's, glucans, oil-in-water emulsion, MPL, muramyl dipeptide, muramyl dipeptide derivatives, agonists of TLRs (TLR1 to TLR 13) such as MPL, MDP, Imiquimod, poly (I:C), CpG oligonucleotides, Non-CpG oligonucleotides, saponins such as QS-1, ISCOM, ISCOMATRIX, vitamins or immunomodulants such as cytokines, IL-12, IL-15 etc.
- the stabilizer used in the composition of the present invention is selected from the group comprising one or more of sugar such as 5-40% Trehalose or sugar alcohols such as 5
- the vaccine composition according to invention comprises vaccine antigens of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) expressed in E.Coli using the pTWINl plasmid and purified proteins by self cleavage, by temperature from 50-65°C and pH shift ranges from pH 6.5 to 7.5.
- EGFL SEQ ID No. 6
- E1FS1 SEQ ID No. 7
- E1FS2 SEQ ID No. 8
- SEQ ID No. 9 E2FS1
- SEQ ID No. 10 E2FS2
- SEQ ID No. 16 BsE2FSl
- SEQ ID No. 17 EGFL2
- SEQ ID No. 18 FliC
- SEQ ID No. 19 SDM
- SEQ ID No. 20 comprising the following steps:
- iii purification of proteins by at least one or two of the following methods: ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction column chromatography.
- the high cell density growth media as used for isolation and purification of chimeric proteins in the claimed invention comprises 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgS0 4 , 1M CaCh, Biotin, Thiamine and ampicillin.
- vaccine composition comprising the chimeric protein sequence as disclosed in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) which are at least 90% - 96% pure.
- a method of treatment to regulate the tumor growth or to increase the survival rate comprising therapeutic vaccine composition according to invention with or without Tyrosine Kinase Inhibitors (TKIs).
- TKIs Tyrosine Kinase Inhibitors
- the Tyrosine Kinase Inhibitor comprises 1 st or 2 nd or 3 rd generation TKIs such as Geftinib, Erlotininb, Afatinib, Dacomitinib, Avitinib, Olmutinib or Nazartinib.
- the vaccine composition according to the present invention is stable for at least 2 years at 2-8°C and up to 1 to 72 weeks at 37°C.
- vaccine composition with immunogenic molecule a synthetic construct selected from the recombinant chimeric protein sequences as represented in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2); (b) adjuvants, either immunomodulator or delivery system and (c) stabilizers, wherein the said vaccine composition is stable for at least 2 years at 2-8 °C and 1 to 2 weeks at 37°C.
- a process for treating a tumor induced mouse model includes administering therapeutic vaccine, which contains growth factor & pharmaceutically acceptable carrier protein that shows an adjuvant property to promote an immune response. Further, it also discloses the use of tyrosine kinase inhibitor, as a first line treatment followed by therapeutic vaccination to treat tumor induced mouse model.
- Figure 1 Protein expression, purification and characterization of EGFL.
- Figure 1A depicts SDS-PAGE of EGFL chimeric protein expressed in BL21 cells, induced with IPTG.
- Figure IB represents EGFL (before and after cleavage) and its purified elution fractions by ion-exchange chromatography.
- Figure 1C elucidates characterization of EGFL (before and after cleavage) by western blot using Human Anti-EGF antibody.
- Figure ID shows purified EGFL by Size Exclusion chromatography.
- Figure IE shows purified protein EGFL by affinity chromatography using CBD (chitin binding domain) resin.
- Figure IF depicts the yields of EGFL protein tested in different media.
- FIG. 2A SDS-PAGE gel depicts the expression of E1FS1 (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
- Figure 2B elucidates characterization of E1FSI (before and after cleavage) by western blot using Human Anti-EGF antibody.
- FIG. 2C SDS-PAGE gel depicts the expression of E2FS1 (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
- Figure 2D elucidates characterization of E2FS1 (before and after cleavage) by western blot using Human Anti-EGF antibody.
- FIG. 2E SDS-PAGE gel depicts the expression of FliC (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
- FIG. 2F SDS-PAGE gel depicts the expression of SDM (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
- Figure 2G illustrates western blot representing the E. coli expressed recombinant huEGF, recognized by the vaccinated sera raised against EGFL.
- Figure 3A illustrates a bar graph quantification of exposed EGF epitopes in its conformational form of EGFL or E1FS1 or E2FS1 chimeric proteins, anti-EGF antibody using huEGF quantification kit.
- Figure 3B illustrates a bar graph of anti-FliC antibody binding to recombinant full length FliC or truncated flagellin (SDM) or EGFL or E1FS1 or E2FS1 proteins that were captured on to ELISA plates.
- SDM truncated flagellin
- Figure 4A illustrates dose response curve generated by EGFL activity as an immunopotentiator, when stimulated with HEK Blue reporter cells engineered with TLR5.
- This figure represents dose response curve generated by EGFL activity as an immunopotentiator, when stimulated with HEK Blue reporter cells that were engineered with TLR5.
- Flagellin (FliC) was taken as a positive control.
- X-axis represents concentration of protein in log scale and Y-axis represents % response of protein.
- Each data set point is represented as a Mean+SD, which was obtained from three independent experiments done in duplicates.
- Figure 4B illustrates dose response curve generated by E1FS1 & E2FS1 activity as an immunopotentiator, when stimulated with HEK Blue reporter cells engineered with TLR5.
- This figure represents dose response curve generated by E1FS1 & E2FS1 activity as an immunopotentiator, when stimulated with HEK Blue reporter cells that were engineered with TLR5.
- Truncated Flagellin (SDM) was taken as a control.
- X-axis represents concentration of protein in log scale and Y-axis represents % response of protein.
- Each data set point is represented as a Mean+SD, which was obtained from three independent experiments done in duplicates.
- Figure 4C The graph shows secreted IL-8 cytokine by EGFL, by stimulating genetically engineered HEK Blue reporter cells with TLR5 gene.
- EGFL secreted approximately 700pg/ml IL-8 cytokine, whereas FliC secreted 200pg/ml.
- Figure 5 Anti cell prolification growth pattern of NCI-H1975 cells, when treated with (Figure 5A): vaccinated sera against raised against EGFL, E1FS1, E2FS1, FliC and SDM (purified commercial anti-EGF antibody used as positive control); and ( Figure 5B): combination of Geftinib and vaccinated sera against EGF, EGFL, E1FS1, E2FS1, FliC and SDM.
- Figure 6A Antibody titer raised against chimeric EGFL in mice.
- Figure 6B ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing EGFL.
- Figure 6C ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing E1FS1.
- Figure 6D ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing E2FS1.
- Figure 6E represents Thl:Th2 index of anti-EGF isotype antibody elicited against chimeric proteins.
- Figure 7A ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing EGFL
- Figure 7B ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing E1FS1
- Figure 7C ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing E2FS 1
- Figure 8A ELISA assay to represent EGF specific endpoint titer elicited against EGFL, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants.
- X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
- Figure 8B ELISA assay to represent EGF specific endpoint titer elicited against E1FS1, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants.
- X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
- Figure 8C ELISA assay to represent EGF specific endpoint titer elicited against E2FS1, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants.
- X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
- Figure 9 Determination of tumor growth pattern induced by two different cell densities of LLC1 (Lewis Lung Cancer Cell line) in mice at different time points, so as to assess the ideal cell density to generate mice tumor model for therapeutic vaccination.
- This graph shows that mice started developing tumor from Day 7 onwards. Mice that received lxlO 6 cells/mouse, shown rapid tumor development, whereas mice that received 0.2xl0 6 cells/mouse have shown slow tumor growth.
- high cell density was selected to generate mice induced tumor model.
- Figure 10A Represents rate of tumor growth before and after treatment.
- X-axis indicates day on which tumor was measured and Y-axis indicates tumor volume. Tumor size increased drastically in mice after receiving tumor cells upto day 17, thereafter, slow tumor growth was observed immediately after receiving vaccination.
- Figure 10B Anti-EGF antibody response and EGF levels in serum are very well correlated thus proving immuno therapeutic activity of chimeric EGFL.
- Figure 11 illustrates the survival graphs of tumor induced mice when treated with EGFF (as depicted in Figure 11A), E1FS1 (as depicted in Figure 11B), and E2FS1 (as depicted in Figure 11C). Further Figure 11D, Figure HE, and Figure 11F represents tumor induced mice treated with EGF, FliC and SDM respectively used as control.
- Figure 12 Depicts survival rate of mice treated with Geftinib alone (Figure 12A) and in combination with EGFF ( Figure 12B).
- the present disclosure provides a construction of recombinant chimeric protein expressing full length or truncated flagellin and a human epidermal growth factor (EGF) is described. Further, in one illustrative embodiment, construction of recombinant chimeric protein comprising one or more copies of growth factor to improve the presentation of the maximum number of growth factor epitopes. It is contemplated within the scope of the disclosure that such recombinant chimeric proteins are highly immunogenic to the human immune system. Preferably, the recombinant proteins confer additional properties to the chimeric protein, for example, high expression yield and ease of manufacture and stability.
- the recombinant proteins whether one or more copies of growth factor fused with either full length or truncated flagellin elicits broad range of immune responses against EGF (epidermal growth factor).
- EGF epidermal growth factor
- these EGF based chimeric proteins may be useful in treating chronic diseases, for example, breast, lung, bladder, ovarian, Vulva, colonic, pulmonary, brain, colorectal, intestinal, head and neck, and esophagus cancers, where, EGF is responsible for uncontrolled cell proliferation.
- the present invention discloses construction of codon optimized chimeric genes and its expression, purification & characterization.
- Chimeric gene encodes Epidermal Growth Factor (EGF) and a full length or truncated flagellin (without hypervariable region, from the position 178 to 405 amino acids).
- EGF Epidermal Growth Factor
- the present invention also describes the function of the flagellin both as an adjuvant and anti-tumorigenic property.
- the present invention also discloses that the purified chimeric protein was able to elicit high titer antibodies against EGF in C57BL/6 mice and also substantially increased survival rate, by reducing the tumor progression rate.
- a vaccine composition for immunotherapy against cancer comprising:
- a physiologically acceptable buffer selected from phosphate and citrate.
- the vaccine composition of the present invention comprises the vaccine antigen comprising one or more of the chimeric protein sequences as represented by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2).
- the vaccine composition of the present invention comprises chimeric protein as vaccine antigen obtained from a codon optimized gene sequences comprising one or more of as represented by SEQ ID No. 1. (EGFL), SEQ ID No. 2 (E1FS1), SEQ ID No. 3 (E1FS2), SEQ ID No. 4 (E2FS1), SEQ ID No. 5 (E2FS2), SEQ ID No. 11 (BsE2FSl) or SEQ ID No. 12 (EGFL2).
- SEQ ID No. 1. EGFL
- E1FS1 SEQ ID No. 2
- E1FS2 SEQ ID No. 3
- SEQ ID No. 4 E2FS1
- SEQ ID No. 5 E2FS2
- SEQ ID No. 11 BsE2FSl
- SEQ ID No. 12 EGFL2
- the vaccine composition of the present invention comprises chimeric protein as vaccine antigen, which comprises of growth factor linked to N-terminal or C- terminal or middle of the full length or truncated carrier protein and is genetically synthesized.
- the chimeric protein is expressed in prokaryotic expression system through a prokaryotic expression plasmid.
- the growth factor is human EGF.
- the human EGF epitopes are exposed on the surface of the chimeric proteins.
- the composition of the present invention comprises genetically synthesized full length Flagellin protein as carrier protein.
- the carrier protein in the vaccine composition of the present invention is a genetically synthesized truncated Flagellin protein without the hypervariable region which are from amino acid numberl78 to amino acid number 405.
- the genetically synthesized sequence is selected from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g— protcobactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
- the carrier protein the vaccine composition of the present invention helps the immune system to recognize autologous EGF to induce immune response against EGF and acts as adjuvant to enhance Th2 responses or B cell mediated immune responses.
- the adjuvant present in the composition of the invention is selected from one or more of a group of aluminium salt such as aluminium phosphate or aluminium hydroxide, squalene based adjuvants such as MF59, montanide, RIBI adjuvant, incomplete Freund's, glucans, oil-in-water emulsion, MPL, muramyl dipeptide, muramyl dipeptide derivatives, agonists of TLRs (TLR1 to TLR 13) such as MPL, MDP, Imiquimod, poly (I:C), CpG oligonucleotides, Non-CpG oligonucleotides, saponins such as QS-1, ISCOM, ISCOMATRIX, vitamins or immunomodulants such as cytokines, IL-12, IL-15 etc.
- aluminium salt such as aluminium phosphate or aluminium hydroxide
- squalene based adjuvants such as MF59, montanide, RIBI adj
- the stabilizer used in the composition of the present invention is selected from the group comprising one or more of sugar such as 5-40% Trehalose or sugar alcohols such as 5-40% Glycerol or 5-40% Sorbitol.
- the vaccine composition according to invention comprises vaccine antigens of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) expressed in E.Coli using the pTWINl plasmid and purified proteins by self cleavage, by temperature from 50-65°C and pH shift ranges from pH 6.5 to 7.5.
- EGFL SEQ ID No. 6
- E1FS1 SEQ ID No. 7
- E1FS2 SEQ ID No. 8
- SEQ ID No. 9 E2FS1
- SEQ ID No. 10 E2FS2
- SEQ ID No. 16 BsE2FSl
- SEQ ID No. 17 EGFL2
- SEQ ID No. 18 FliC
- SEQ ID No. 19 SDM
- SEQ ID No. 20 comprising the following steps:
- iii purification of proteins by at least one or two of the following methods: ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction column chromatography.
- the high cell density growth media as used for isolation and purification of chimeric proteins in the claimed invention comprises 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgSCC, 1M CaCh, Biotin, Thiamine and ampicillin
- vaccine composition provided with immunogenic molecule, a synthetic construct selected from the recombinant chimeric protein sequences as represented in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2); (b) adjuvants, either immunomodulator or delivery system and (c) stabilizers, wherein the said vaccine formulation is stable for at least 2 years at 2-8 °C and 1 to 2 weeks at 37°C.
- the vaccine composition comprises chimeric protein sequence as disclosed in SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2) which are at least 90% - 96% pure.
- a method of treatment to regulate the tumor growth or to increase the survival rate comprising therapeutic vaccine composition according to invention with or without Tyrosine Kinase Inhibitors (TKIs).
- the Tyrosine Kinase Inhibitor comprises 1 st or 2 nd or 3 rd generation TKIs such as Geftinib, Erlotininb, Afatinib, Dacomitinib, Avitinib, Olmutinib or Nazartinib.
- the vaccine composition according to the present invention is stable for at least 2 years at 2-8°C and up to 1 to 2 weeks at 37°C.
- Recombinant chimeric proteins were created expressing the entire EGF coding region on the full length or truncated flagellin at either at the N or C-terminus or in place of hypervariable D2 & D3 domains or D3 region of flagellin.
- Flagellin in synthetic chimeric protein may contain protein sequence similar to flagellin sequence from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g-proteobacteria such as Salmonella typhimurium or enterica species or b-proteobacteria such as Bordetella. Construction of each chimeric genes of the present invention is as detailed in examples 1.1 to 1.8
- EGF fused to full length or truncated flagellin either at N- or C- termini of the full length or truncated flagellin with the help of linkers. Additional recombinant EGF is again fused either at N- or C-termini or at the middle of the full length flagellin by restriction enzyme.
- linkers can reduce steric hindrance and may also enable unique restriction sites to be introduced within the linkers to allow subsequent manipulation of the genetic constructs.
- amino acid linkers were used, but not limited to EAAAKP, AS and AAA.
- Plasmid pTWINl express the target gene, under the control of T7 promotor, which is regulated by IPTG or Lactose due to the presence of Lac I gene.
- the purpose of using the pTWIN 1 vector is due to its advantage of controllable self cleavage of modified Sap DnaB (Mathy, S et al., (1999) Gene.
- Example 1.1 Construction of plasmid encoding EGFL_Nucleic acid sequence of EGFL includes autologous human EGF at N-terminus of full length flagellin and these two sequences are connected by a linker.
- the whole gene comprising of 1698bps (Seq ID No. 1) and the corresponding translated protein sequence (SEQ ID No. 6) contains 565 amino acids with a molecular weight of approximately 62 kDa.
- EGFL was amplified by PCR from pUC57-LC-EGFL (which was genetically synthesized sequence from Genscript) using appropriate primers to introduce Sapl site at the N-terminus of EGFL.
- This PCR fragment digested with Sapl & Pstl restriction enzymes and was ligated into pUC57 & pTWIN 1 vectors and named as pUC57 EGFLWO & pTWIN 1 EGFL respectively.
- plasmid pTWINl encoding EGFL was transformed into DH5alpha. Single cell colonies were selected from the plate containing 100 pg/mL ampicillin, grown overnight at 37 °C. These clones were screened by restriction digestion and confirmed by nucleotide sequencing using the appropriate sequencing primers.
- Example 1.2 Construction of plasmid encoding E1FS1 Nucleic acid sequence of E1FS1 consists of autologous human EGF at N-terminus of truncated flagellin with deletion of hypervariable region D2 & D3 region (amino acids from position 178 to 405aas). E1FS1 gene sequence was generated by deleting hypervariable regions D2 & D3 from EGFL by site directed mutagenesis. The whole gene comprising of 1017bps (Seq ID No. 2) and the corresponding translated protein sequence (SEQ ID No. 7) contains 338 amino acids with a molecular weight of approximately 37 kDa.
- hypervariable region (position 178 to 405aas) of flagellin was deleted from pUC EGFL (WO), using appropriate primers and purified the circularized plasmid containing E1FS1, after Dpn digestion.
- E1FS1 fragment from pUC57 was digested with Sapl & Pstl, and ligated into pTWINl vector. After transformation into DH5alpha, clones were screened by restriction digestion and confirmed by DNA sequence using appropriate sequencing primers.
- Example 1.3 Construction of plasmid encoding E1FS2 Nucleic acid sequence of EFS2 consists of autologous human EGF at N-terminus of truncated flagellin with deletion of hypervariable region D3 region (amino acids from position 186 to 285aas). E1FS2 gene sequence was generated by deleting hypervariable regions D3 from EGFL by site directed mutagenesis. The whole gene comprising of 1401bps (Seq ID No. 3) and the corresponding translated protein sequence (SEQ ID No. 8) contains 466 amino acids with a molecular weight of approximately 51 kDa.
- Plasmid pUC57-ElFS2 where hypervariable region D3 (position 186 to 285aas) of flagellin was deleted from pUC EGFL (WO), using appropriate primers and purified the circularized plasmid containing E1FS2, after Dpn digestion.
- E1FS2 fragment from pUC57 was digested with Sapl & Pstl, and ligated into pTWINl vector using the same restriction sites. After transformation into DH5alpha, clones were screened by restriction digestion and confirmed by DNA sequence using appropriate sequencing primers.
- Example 1.4 Construction of plasmid encoding E2FS1 Nucleic acid sequence of E2FS1 consists of 2 copies of autologous human EGF and truncated flagellin with deletion of D2 & D3 region. E2FS1, wherein, 1 copy of EGF located at N-terminus and another copy located within the sequence of the flagellin (in place of D2 & D3 region). E2FS 1 gene sequence was generated by introducing second copy of EGF into E1FS1 using Nhel site as linker. The whole gene comprising of 1185bps (Seq ID No. 4) and the corresponding translated protein sequence (SEQ ID No. 9) contains 394 amino acids with a molecular weight of approximately 43 kDa.
- E2FS1 plasmid pUC57-ElFSl was digested with Nhel and used as a vector after gel purification.
- the second copy of EGF insert which was amplified from the pUC EGFL (WO or the previous one) with Nhel sites at both N- & C-terminus using appropriate primers was ligated.
- E2FS1 was inserted into pTWINl plasmid using Sapl & Pstl from pUC57-E2FSl. Clones were screened by restriction digestion and confirmed by nucleotide sequencing using appropriate primers.
- Example 1.5 Construction of plasmid encoding E2FS2 Nucleic acid sequence of E2FS2 consists of 2 copies of autologous human EGF and truncated flagellin with deletion of D3 region. E2FS2, wherein, one copy of EGF located at N-terminus and another copy located within the sequence of flagellin (in place of D3 region). E2FS2 gene sequence was generated by introducing second copy of EGF into E1FS2 with the help of Nhel restriction site as a linker. The whole gene comprising of 1569bps (Seq ID No. 5) and the corresponding translated protein sequence (SEQ ID No. 10) contains 522 amino acids with a molecular weight of approximately 57 kDa.
- the plasmid (pTWINl-E2FS2) was constructed using sapl & pstl restriction enzymes and the plasmid was transformed into DH5a. Single cell positive colonies were selected from the plate containing 100 pg/mL ampicillin grown overnight at 37°C. These positive colonies were further confirmed by nucleotide sequencing.
- Example 1.6 Construction of plasmid encoding BsE2FSl: Nucleic acid sequence of BsE2FSl consists of 2 copies of autologous human EGF and flagellin derived from Bacillus subtilis (strain 168), wherein, 1 copy of EGF located at N-terminus and another copy at the C- terminus of flagellin.
- the whole gene comprising of 1260bps (Seq ID No. 11) and the corresponding translated protein sequence (SEQ ID No. 16) contains 420 amino acids with a molecular weight of approximately 46 kDa.
- BsE2FSl was a synthetic sequence from pUC57 vector was digested with Sapl & Pstl and ligated into Sapl & Pstl digested pTWINl vector. After ligation, Plasmid pTWINl encoding BsE2FSl was transformed into DH5alpha and positive clones were screened by restriction digestion and confirmed by nucleotide sequencing done using appropriate primers.
- Nucleic acid sequence of EGFL2 includes 2 copies of autologous human EGF both at N- & C- terminus of full length flagellin and these two sequences are connected by a linker.
- the whole gene comprising of 1863 bps (Seq ID No. 12) and the corresponding translated protein sequence (SEQ ID No. 17) contains 621 amino acids with a molecular weight of approximately 79 kDa.
- second copy of EGF was introduced to full length flagellin at the C- terminus using Nhel site using FW Nh & Rv Pst in pUC57.
- EGFF2 sequence from pUC57 was digested with Sapl & Pstl and ligated into Sapl & Pstl digested pTWINl vector. After ligation, Plasmid pTWINl encoding EGFF2 was transformed into DH5 alpha and positive clones were screened by restriction digestion and confirmed by nucleotide sequencing done using appropriate primers.
- Example 1.8 Construction of plasmid encoding recombinant Full length (FliC) or truncated flagellin: (SDM- deletion of hypervariable region D2 & D3 of flagellin)
- Example 1.8a Nucleic acid sequence of FFiC includes full length flagellin. The whole gene comprising of 1518 bps (Seq ID No. 13) and the corresponding translated protein sequence (SEQ ID No. 18) contains 506 amino acids with a molecular weight of approximately 55 kDa.
- FliC was amplified by PCR from pUC57-FC-EGFF (genetically synthesized sequence) using appropriate primers. This insert was ligated into Sapl & Pstl digested pTWINl vector. Plasmid pTWINl encoding FliC was transformed into DH5alpha and positive clones were screened by digestion (Pstl & Xbal) and confirmed by DNA sequencing using the appropriate primers.
- Example 1.8b Construction of truncated Flagellin (SDM)_Nucleic acid sequence of SDM EGFF includes truncated flagellin with deletion of hypervariable region D2 & D3 region (amino acids from position 178 to 405aas).
- the whole gene comprising of 837 bps (Seq ID No. 14) and the corresponding translated protein sequence (SEQ ID No.19) contains 279 amino acids with a molecular weight of approximately 30 kDa.
- SDM was amplified from pUC57 E1FS1, clone#5 using appropriate primers. PCR fragment was purified and digested with Sapl & Pstl and used as insert. This insert was introduced into the Sapl & Pstl digested pTWINl by ligation. After ligation, plasmid pTWINl containing SDM was transformed into DH5alpha and positive clones were selected by digestion with Nhel & Pstl and confirmed by sequencing using appropriate primers.
- Example 1.9 Construction of plasmid encoding Epidermal Growth Factor (EGF):_Nucleic acid sequence of autologous human EGF comprising of 162bps (Seq ID No. 15) and the corresponding translated protein sequence (SEQ ID No. 20) contains 54 amino acids with a molecular weight of approximately 6.2 kDa.
- EGF Epidermal Growth Factor
- Plasmid pTWINl containing EGF was generated by ligating Sapl & Pstl digested pTWINl vector and also PCR amplified EGF from the plasmid that has genetically synthesized sequence of EGF. After ligation, Plasmid pTWINl encoding EGF was transformed into DH5alpha and positive clones were confirmed by digestion (Pstl & Nhel) and sequence was confirmed by DNA sequencing using the appropriate primers.
- pTWINl expression plasmid constructs encoding genes such as [(EGF, full length flagellin (FliC) or truncated Flagellin (SDM)] were also generated to express recombinant proteins such as (EGF, FliC, SDM respectively) and used as controls in both in-vitro and in- vivo studies.
- a summary is provided as per the below Table 1 for all the Nucleic Acids and recombinant proteins:
- Example 2 Expression & Characterization of Chimeric Proteins:
- the bacterial culture was induced with 0.2 - 1 mM IPTG for 16-18 h (as shown in Figure 1A). Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and resolved proteins on SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. Further, the gel with expressed protein having MW 85kDa (before cleavage) and 62kDa (after cleavage) was transferred on to a nitrocellulose membrane for a western blot.
- Mouse anti-hEGF antibody (Abeam, Cat#abl0409) and HRP-labeled goat- anti-mouse IgG were used as primary and secondary antibody respectively.
- 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate.
- Western blot analysis determined that the chimeric protein EGFL displays the EGF epitopes in the correct conformation and thus EGFL is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 1C.
- BL21 (DE3) cells were grown in different media compositions (PP, LBM9, CYM9 media or enriched media), while testing in different induction protocols, using Lactose as inducer.
- PP Media Single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in PP media composed of 40% glucose, M9 salt solution, trace elements, 1M MgS04, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5. Further it was induced with 0.5% lactose and incubated overnight at 25°C. Cells were finally harvested further processed for protein extraction and purification.
- LBM9 media Single colony was inoculated from a fresh transformed plate into 5 ml of LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in LBM9 media composed of 2% LB media, 40% glucose, M9 salt solution, trace elements, 1M MgSC , 1M CaCF, Biotin, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5. Further it was induced with 0.5% lactose and incubated overnight at 25°C. Cells were finally harvested by and further processed for protein extraction and purification.
- BBIL-CYM9 Media In this disclosure, bacterial culture was grown in the below mentioned media to obtain high cell density and then induced with lactose to increase the yield. Briefly, single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10 % inoculum was used for secondary culture in CYM9 media composed of 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgSCL, 1M CaCb, Biotin, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5.
- the present invention also discloses the abovementioned novel media, namely BBIL-CYM9 used with double induction.
- Enriched media Single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in enriched media composed of 1.5% yeast extract, 1.5% Casein, 2% glycerol, M9 salt solution, trace elements, 1M MgS04, Thiamine and ampicillin and incubated at 37°C till the OD reaches 0.4-0.6. Culture was then induced with 0.2% lactose and incubated for 3 hrs at 37°C. Induced culture was used as inoculum (10%) for inoculating tertiary culture and incubated at 37°C, 250 rpm till the OD reaches 3. Further it was induced with 0.2% lactose and incubated overnight at 25°C. Cells were finally harvested by centrifugation at highest rpm for 20 minutes and further processed for protein extraction.
- Example 2.2 Expression & Characterization of E1FS1: The plasmid (pTWINl-ElFSl) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37 °C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions.
- the expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) (as shown in Figure 2A).
- the gel was transferred to a nitrocellulose membrane for a western blot.
- Mouse anti-hEGF antibody and HRP-labeled goat-anti-mouse IgG were used as primary and secondary antibody respectively.
- 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate.
- Western blot analysis determined that the chimeric protein E1FS1 can display the EGF epitopes in the correct conformation and thus E1FS1 is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 2B.
- Example 2.3 Expression & Characterization of E2FS1: The plasmid (pTWINl-E2FSl) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions.
- the expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) (as shown in Figure 2C).
- the gel was transferred to a nitrocellulose membrane for a western blot.
- Mouse anti-hEGF antibody and HRP-labeled goat-anti-mouse IgG were used as primary and secondary antibody respectively.
- 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate.
- Western blot analysis determined that the chimeric protein E2FS1 can display the EGF epitopes in the correct conformation and thus E2FS 1 is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 2D.
- Example 2.4 Expression & Characterization of FliC: The plasmid (pTWINl-FliC) was again transformed into E. coli BF21 (DE3) competent cells. Single colony was isolated and grown in FB medium containing 100 pg/mF amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions.
- SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
- Example 2.5 Expression & Characterization of SDM: The plasmid (pTWINl-SDM) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions.
- SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis
- Example 2.6 Expression & Characterization of HuEGF:
- the plasmid (pTWINl-EGF) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 h. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes.
- SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions.
- the expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis).
- the gel was transferred to a nitrocellulose membrane for a western blot.
- Mouse vaccinated sera raised against EGFL was used to probe huEGF as a primary antibody and HRP-labeled goat- anti-mouse IgG was used as secondary antibody.
- 3,3 -diaminobenzidine tetrahydrochloride (DAB) was used as a substrate.
- Example 3 Isolation, purification & characterization of recombinant proteins:
- the given illustrative embodiment discloses the isolation and purification protocol for all recombinant proteins that were disclosed in the present invention.
- the E. coli culture pellet was resuspended in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 150 mM NaCl, pH 8.5) with lysozyme (1 mg/ml). Then, DNase and MgCF were added with agitation at 4°C. The cell culture was subjected to sonication with conditions (40 amplitude for 10 seconds ON’ & 10 seconds OFF’, later 70 amplitude for 30 minutes with 10 seconds ON’ and 10 seconds OFF’) and after sonication sample was centrifuged at 12000 rpm for 15-20 minutes. Pellet & Supernatant was separated & checked by SDS-PAGE.
- Protein was found in supernatant in soluble form and the solution was kept at 4°C.
- This protein solution was dialyzed against cleavage buffer (20 mM Tris-Cl, 2 mM EDTA, 150 mM NaCl, pH 6.0 & 5% glycerol) for 48-72 hours at RT. Temperature (from 4°C to RT) & pH shift (from pH 8.5 to pH range from 6.5 - 7.5) was done to induce Ssp DnaB intein self-cleavage. Finally, the solution was subjected to heat treatment at 50-65°C for 30 minutes and supernatant was collected by centrifugation at 12000 rpm for 10 minutes at 4°C.
- cleavage buffer (20 mM Tris-Cl, 2 mM EDTA, 150 mM NaCl, pH 6.0 & 5% glycerol
- the supernatant containing desired protein was further subjected to protein purification by ion exchange chromatography (IEC) followed by Size exclusion chromatography (SEC) to achieve higher purity of upto 99% of the targeted protein.
- IEC ion exchange chromatography
- SEC Size exclusion chromatography
- higher purity of up to 99% pure protein may also be obtained using either one of the following methods or in combination such as Ion-exchange chromatography or affinity chromatography using CBD (Chitin Binding Domain) resin or hydrophobic interaction chromatography or Size exclusion chromatography or chromatography using mixed mode resins.
- Example 3.1 Ion Exchange Chromatography (IEC): The suspension of heated or cleaved mixture was directly injected into a MacroPrep High Q 3HT strong anion exchange resin obtained from Biorad. Resin was equilibrated with 3 volumes of equilibration buffer pH 6.5 (20 mM Tris, 0.2 mM EDTA, 150 mM NaCl, 0.01 % sodium azide, 0.1 % Tween 20 & 0.1 % Triton X-114). The sample was loaded on to the column with a flow rate 0.5 ml/min.
- IEC Ion Exchange Chromatography
- the desired chimeric protein that is devoid of intein CBD tag was collected by elution buffer (20 mM Tris-Cl, 0.2 mM EDTA, 400mM NaCl, pH 7.5) with a flow rate 1 mL/min.
- Purified IEC fractions of chimeric proteins EGFL, E1FS1 and E2FS1 are illustrated in Figure IB, Figure 2A and Figure 2C respectively and IEC purified recombinant proteins such as FliC, and SDM are illustrated in Figure 2E and 2F respectively.
- Example 3.2 Size exclusion chromatography (SEC): Superdex 200 resin packed in XK16/60 column was used to purify the recombinant chimeric protein(s). Initially, column was equilibrated with IOC Vs of equilibration buffer (lxPBS, pH 7.4). Sample was loaded at a flow rate of 0.5 ml/min followed by desired protein elution at a flow rate of 0.8 ml/min. Purified SEC fractions of chimeric proteins EGFF, E1FS1 and E2FS1 are illustrated in Figure ID, Figure 2A and Figure 2C respectively and SEC purified recombinant proteins such as FliC, and SDM are illustrated in Figure 2E and 2F respectively.
- SEC Size exclusion chromatography
- Example 3.3 Affinity Chromatography: To remove intein associated chitin binding domain, which was expressed along with chimeric proteins, the affinity column packed with chitin resin was used. The chitin resin was equilibrated with 10 column volumes (CVs) of equilibration buffer (20 mM Tris-Cl, 500 mM NaCl, 1 mM EDTA, 0.1% Tween 20, pH 8.5) followed by sample loading on to the column with a flow rate 0.5 ml/min or less. Column was washed with 10 CVs equilibration buffer.
- CVs column volumes
- Example 4.1 Determination of EGF epitope binding and its quantification by ELISA:
- Quantification of Human EGF by ELISA The assay was done as per the instructions given in the manual. Briefly, 96 well plate coated with anti-EGF antibody (capture antibody) was used. Later, Standards, control (EGF) or pre diluted Recombinant protein samples such as EGFL or E1FS1 or E2FS1 or BsE2FSl or EGFL2 (IOOmI of each sample/per well) were added to each well and incubated it for 2 hours. The plate was washed four times with PBS containing 0.5% Tween (PBST). Further, Biotin conjugated anti-Hu EGF antibody (100 m ⁇ /well) was added and incubated the plate at room temperature for lhr.
- EGF E1FS1 or E2FS1 or BsE2FSl or EGFL2
- Table 4 Theoretical equimolar ratios of EGF & FliC or SDM in each chimeric construct and the estimated EGF concentration by EFISA.
- Example 4.2 Relative estimation of Full Length or truncated Flagellin by ELISA: To assess, the relative amount of flagellin epitopes exposed in chimeric proteins, 96 well plate was coated with 100 pi of each protein at equal concentration (1 pg/ml), diluted in PBS, pH 7.4. Plate was incubated for overnight at 4C. Subsequently 3 washes with PBST were carried out and then the plates were blocked with a solution of 1 x PBS containing 0.5% skim milk, incubated them during a period of 1 hour at RT. Next step, the plates were incubated with 50 ul/well of anti-mouse-FliC antibody HRP conjugate (1:5000 dilution) for 1 hour at RT. Reaction color was developed with TMB 50 ul/well, incubated for 30 minutes at RT. Optical density was measured at 450 nm in an ELISA plate reader.
- Example 4.3 Adjuvant activity of FliC or SDM in chimeric constructs: Flagellin has the ability to bind to TLR5 receptors that are present on the surface of the immune cells, so as to stimulate immune response.
- TLR5 Toll Like Receptor 5
- PRRs pattern recognition receptor
- TLR5 reporter cell lines i.e HEK-Blue Human TLR5 reporter cell lines
- Example-4.3a Cell lines and treatments: HEK - Blue Human TLR5 reporter cell lines purchased from Invivogen, California, USA. These cells were prepared by co-transfection of human TLR5 gene and codon-optimized SEAP (secreted embryonic alkaline phosphatase) as a reporter gene into HEK 293 cells. Cell lines were cultured in DMEM, 4.5 g/1 glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 pg/ml streptomycin, 100 pg/ml NormocinTM.
- DMEM 4.5 g/1 glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 pg/ml streptomycin, 100 pg/ml NormocinTM.
- NFkB Upon stimulation of cells with chimeric fusion proteins containing full length or truncated flagellin, NFkB gets activated, which in-tum secrets SEAP and it was measured in cell supernatant using spectrophotometer at wavelength 630-650 nm.
- Example-4.3b TLR5 Specific Reporter Assay: HEK - Blue Human TLR5 reporter cells (5xl0 4 / well) were plated and cultured overnight in a humidified CO2 incubator at 37°C. Next day, cells were treated with various concentrations of chimeric fusion protein/s, (0.0001 to 1000 ng/ml) and cultured for 16 hours. Cells were also treated with Flagellin (FliC) or truncated flagellin (SDM) as a positive control. EGF was also tested for TLR5 activity, but EGF didn’t show any activity (hence results not shown). Supernatant was collected and treated with Quanti blue detection reagent at 37°C for 15-30 minutes. Absorbance was read at 630 nm.
- FliC Flagellin
- SDM truncated flagellin
- Dose response curve was generated by plotting concentration of protein on X-axis and % response on the Y-axis is as shown in Figure 4A and Figure 4B. To generate dose response curve, highest absorbance shown at tested concentration was taken as 100% response and the least absorbance was taken as 0% response. Effective concentration at 50% (EC50) response was determined from the dose response curve.
- proteins showed maximum 100% response with a high absorbance at 1000 ng/ml concentration (reached plateau at this concentration in sigmoidal curve), whereas, 0% response with a low absorbance at 0.0001 ng/ml concentration.
- EC so 3.5, 0.006, 0.01, 0.99 & 0.08 ng/ml of EGFL, E1FS1, E2FS1, FliC & SDM respectively (concentration at which protein(s) showed half maximal response).
- the results obtained indicated that the chimeric fusion proteins EGFF / E1FS1/ E2FS1 of the present invention were able to stimulate immune cells that express TFR5 receptors, which in-tum determines its ability to enhance immune response and thereby has the capacity to act as an adjuvant as a whole for elevated immune responses, as illustrated in Figure 4A and Figure 4B .
- Example 4.3c Anti-tumorigenic Property Assay ⁇ In-Vitro)’.
- activated macrophages or immune cells that express TFR5 secretes IF-8, which in-tum induces physiological responses that lead to the recruitment of granulocytes, neutrophils at the site of infection or it leads to phagocytosis or chemotaxis.
- Secretion of IF-8 is also a measure of anti-tumorigenic property.
- EFISA to confirm IF-8 secreted by activated immune cells with TFR5 was measured by EFISA, which in-turn signifies the anti- tumorigenic property of the chimeric fusion proteins of the present invention as disclosed in Example 4C above.
- EFISA to estimate IF-8, supernatant collected from stimulated HEK Blue reporter cells with chimeric protein(s) or flagellin was used and performed EFISA as disclosed in the below sections ⁇
- Example 4.3d Determination of IL-8 by ELISA: To quantify human Interleukin 8 (hu IF- 8) in cell culture supernatant, Enzyme Finked Immunosorbent Assay (EFISA) kit purchased from Thermo scientific (Cat#EH2IF8) was used. All reagents, standards, samples were prepared as per the instruction manual. A series of 2.5fold dilutions of standard ranging from (0, 25.6, 64, 160, 400 & 1000 pg/ml) and similarly, 4-fold dilutions (1:4, 1:16 & 1:64) of cell supernatant were prepared to quantitate IF-8 concentration secreted by cells after TFR5 stimulation.
- EFISA Enzyme Finked Immunosorbent Assay
- Example 4.4 Anti-Cell Proliferation Assay: Several antitumor therapies target the EGFR pathway as a way of treatment. However, the use of tyrosine kinase inhibitors (TKIs) namely Geftininb or Erlotinib etc., are one among are the standard treatment in advanced NSCLC with EGFR mutations (Rosell R, et ah, 2012; Maemondo M, et ah, 2010).
- TKIs tyrosine kinase inhibitors
- EGFR mutant NSCLC cell lines NCI-H1975, ATCC, lOxlO 3 cells or PC 9 Cells, ATCC, 3xl0 3 cells
- MTT assay As the EGF is considered to boost the cell proliferation in cancer cells, this experiment is conducted to analyse the anti-proliferative effect of sera raised against chimeric proteins in the presence of EGF on human lung cancer cell line.
- Lung Cancer Cells (NCI-H1975, ATCC, lOxlO 3 cells or PC9 Cells, ATCC, 3xl0 3 cells) were seeded in 96 well plate using RPMI 1640 complete media (10% FBS and 1% PenStrep), allowed to attach for 24 hours at 37°C in 5% CO2 incubator.
- EGF or mouse anti-sera raised against recombinant chimeric proteins EGFL or E1FS1 or E2FS1 or BsE2FSl or E1FS2 or E2FS2
- EGFR TKIs Gelfitinib at IC50 - Inhibitory concentration that causes 50% deaths
- Example 5 Evaluation of mice immune response by the Immunotherapeutic vaccine candidates comprising human epidermal growth factor
- chimeric proteins EGFL or E1FS1 or E2FS1, 50 pg/mouse/100 pi
- mice were also injected with EGF or FliC or SDM.
- EGF was tested at three different concentrations (5, 10 & 16 pg/mouse/100 pi), which is equivalent to 50 pg of EGFL, E1FS1 & E2FS1 respectively.
- EGF concentrations generated based on the equimolar ratio of EGF & FliC or SDM from chimeric proteins.
- Vaccine formulation Chimeric protein (50pg/mouse of EGFL or E1FS1 or E2FS1) in Phosphate buffered saline, pH 7.4 with 5-40% trehalose mixed with aluminium hydroxide in 1 : 1 ratio with a recommended aluminium content.
- Anti-EGF End Point Titer Pooled serum samples were used to determine anti-EGF antibody titer. To perform ELISA, 96 well microtiter plates were coated with huEGF at a concentration [1 or 10 pg/ml, 100 pl/well either in PBS or carbonate buffer (15 mM Na 2 C0 3 , 35 mM NaHC0 3 , pH 9.6)] and kept at 4°C for overnight.
- Threshold (Mean + 3SD) was established by taking the absorbance of negative control (PBS) group. Anti-EGF end point titers were determined after considering the threshold value.
- End point titer representing anti-EGF antibody elicited against chimeric proteins EGFL, E1FS1, and E2FS1 and are depicted in Figure 7A, Figure 7B and Figure 7C respectively. These results demonstrated that EGFL and E2FS1 elicits lesser anti-FliC antibodies as compared to E1FS1.
- Anti-FliC End Point Titer Pooled serum samples were used to determine background elicited against full length or truncated flagellin. To perform this, 96 well microtiter plates were coated with FliC at a concentration [1 or 10 pg/ml, 100 pl/well either in PBS or carbonate buffer (15 mM Na 2 C0 3 , 35 mM NaHC0 3 , pH 9.6)] and kept at 4°C for overnight. Next day, plates were washed with washing buffer (PBST) and blocked with blocking buffer (PBS with 1% BSA) at RT for 1-2 hour.
- PBST washing buffer
- PBS with 1% BSA blocking buffer
- ELISA plates were washed again with wash buffer (PBS, 0.1% TweenTM20) and added 4-fold serial dilutions (in PBS, 0.1% BSA, 0.05% TweenTM20, 0.02% sodium azide) of hyper immunized sera (1;50 to 819200) and incubated at RT for 1 hour. After one hour incubation, wells were washed and added Goat Anti-mouse IgG HRP conjugate (dilution 1:5000) antibody and kept for 1 hour incubation at RT. After incubation, wells were washed, and developed with TMB as a substrate. Absorbance was read at 450 nm.
- Threshold (Mean + 3SD) was established by taking the absorbance of negative control (PBS) group. Anti-FliC end point titers were determined after considering the threshold value.
- IgG sub class (Isotype) determination In order to demonstrate, the type of IgG subclass, pooled mice hyper immunized serum samples were used to perform ELISA. Microtiter (96 well) plates were coated with huEGF at a concentration [1 or lOpg/ml, IOOmI/well either in PBS or carbonate buffer (15 mM Na 2 C0 3 , 35 mM NaHC0 3 , pH 9.6)] and kept at 4°C for overnight.
- adjuvant refers to a specific stimulator of the immune cells which when combined with the chimeric vaccine antigens of the present invention provides an even more enhanced antigen specific immune response.
- various adjuvants aluminum hydroxide and MDP, GMDP and their derivatives, MPL, poly (I:C), CpG etc., were co-administered with the chimeric vaccine antigens either alone or in combination with delivery system (emulsions Oil in Water or Water in Oil etc.,) or combination of one or more of the adjuvants.
- the main objective of this experimental procedure was to demonstrate that the chimeric proteins comprising autologous huEGF are able to show antitumor effect against EGF dependent tumors.
- tumor induced mice model (syngeneic model) was used and the protocol is as mentioned below.
- FECI Fewis Fung Carcinoma 1
- FECI cells were cultured in DMEM medium (Invitrogen). Medium was supplemented with 10% fetal bovine serum (Invitrogen), 100 IU/mF of penicillin, and 100 pg/mF of streptomycin (Invitrogen) and cells grown at 37°C in a humidified incubator containing 5% CO2.
- mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of EGFF.
- Third group of mice received EGF at 5 pg/mouse, which is of equivalent to EGF concentration in EGFL, interms of equimolar ratio.
- Fourth group of mice received FliC at 50 pg/mouse.
- EGF & FliC were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
- HR Hazard Ratio
- mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of E1FS1.
- Third group of mice received EGF at 10 pg/mouse, which is of equivalent to EGF concentration in E1FS1, interms of equimolar ratio.
- Fourth group of mice received SDM at 50 pg/mouse. EGF & SDM were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
- mice treated with E1FS 1 showed 20 % survival benefit, compared to untreated mice (mice received cells alone), which is statistically significant, according to Log rank (Mantel Cox) test with a p value 0.01) and showed, Hazard ratio 2.3 as shown in Figure 11B.
- Mice received EGF & SDM didn’t show significant survival benefit showing Hazard Ratio of 0.93 and 0.63 respectively as shown in Figure 11D and Figure 11 F respectively.
- mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of E2FS1.
- Third group of mice received EGF at 16 pg/mouse, which is of equivalent to EGF concentration in E2FS1, interms of equimolar ratio.
- Fourth group of mice received SDM at 50 pg/mouse.
- EGF & SDM were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
- mice treated with E2FS 1 showed approximately 20% survival benefit, compared to untreated mice (mice received cells alone), showed Hazard ratio of 2.2 as shown in Figure 11C.
- targeted therapy Gafitinib treatment
- therapeutic vaccination with chimeric proteins, EGFL or E1FS1 or E2FS1
- combination Gafitinib treatment followed by therapeutic vaccination with EGFL or E1FS1 or E2FS1
- gefitinib (Gef, 2.5 mg/mouse/dose) treatment was administered on day 5 for up to 3-4 weeks (5 days/week).
- Therapeutic vaccination was given with EGFL or E1FS1 or E2FS1 (50 pg/mouse/dose) on day 7 or 9, followed by 3 vaccinations at an interval of 14 days (i.e at day 7, 21, 35 & 49).
- Mice treated with combination therapy received both targeted therapy for 3-4 weeks along with 3 doses of EGFL or E1FS1 or E2FS1 (50 pg/mouse/dose) vaccination.
- Body weight and tumor size were measured twice a week using weighing balance and vernier callipers, respectively.
- mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality & mice survival rate was determined among groups. Combination of Targeted therapy & immunotherapy showed better survival rate. EGFF protein survived for longer period showing 20% more survival benefit compared to mice received FECI cells alone as shown in Figure 11 A. Further, mice received combination therapy, i.e. Geftinib treatment followed by EGFF treatment showed 50% survival benefit as compared to Geftinib alone with a hazard raio 2.3, as shown in Figure 12A and Figure 12B. The order of survival rate EGFF+Gef (50%) > Gef (19%) > EGFF > FECI. Similar results were found for the E1FS1 and E2FS1 chimeric proteins. In conclusion, these results demonstrated that EGF based Chimeric fusions proteins are in synergy with targeted therapy.
- Example 7.6 Anti-EGF titer determination after therapeutic Vaccination Mice were bled at one day before each vaccination from all groups (both treated, untreated and other control groups), as mentioned in examples 7.2 to 7.5. Serum was collected from blood and used to estimate mouse EGF levels and mouse anti-EGF antibodies by EFISA as given in Example 5.1 and 7.7. Vaccinated groups either individually or combination with Gefitinib induced high anti-EGF antibodies. Mice received combination therapy clearly showed an inverse relation between anti-EGF antibody titer and EGF levels (Figure 10B) estimated in the treated mice (either drug alone or fusion protein or combination therapy), which in turn benefited with increased survival rate (Figure 12A and Figure 12B).
- Example 7.7 Murine EGF Quantitation To evaluate the correlation between the EGF levels and anti-EGF immune response in blood, serum was separated from blood, EGF levels were estimated in both treated & untreated groups using individual mouse sera. To quantify mouse EGF levels, Mouse EGF quantikine EFISA kit (Cat#MEG00) or DY2028 was purchased from R&D systems. All reagents, standard dilutions, Controls and samples were prepared as per the instruction manual. Pre-coated microtiter strips were used to perform ELISA. Serial dilutions of standard or samples prepared as per instructions were added to each well (IOOmI/well) and incubated plate for 2hrs at RT.
- Mouse EGF quantikine EFISA kit Cat#MEG00
- DY2028 was purchased from R&D systems. All reagents, standard dilutions, Controls and samples were prepared as per the instruction manual. Pre-coated microtiter strips were used to perform ELISA. Serial dilutions of standard
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed are recombinant chimeric proteins of human epidermal growth factor that has ability to show both adjuvant activity and anti-tumorigenic property. The present invention discloses the use of recombinant chimeric protein as a therapeutic vaccine composition either in combination with targeted therapies with certain drugs that inhibits signal transduction mechanism for cell proliferation such as tyrosine kinase inhibitors or alone in mice induced tumor model and proved to reduce the progression of a tumor, while considerably increasing the survival period.
Description
A CHIMERIC THERAPEUTIC VACCINE
RELATED PATENT APPLICATION(S)
This application claims the priority to and benefit of Indian Patent Application No. 201841020522 filed on November 30, 2018; the disclosures of which are incorporated herein by reference.
FIELD OF THE INVENTION
The invention relates to biotechnology, particularly biomedical research or immunotherapy. The present disclosure relates to the field of recombinant proteins for use in treating diseases. More specifically, the invention relates to chimeric vaccine comprising human growth hormone sequences and carrier protein encoding the same and methods for expression and using the same as an immunotherapeutic vaccine either alone or in combination with adjuvants to treat Non Small Cell Lung Cancer and other EGF dependant malignant diseases such as breast, bladder, ovarian, vulvia, colon, pulmonary, brain and oesophagus cancers.
BACKGROUND OF THE INVENTION
Cancer is a leading cause of deaths worldwide. Among all cancers, lung cancer is the most common and deadliest cancer causing approximately 1.6 million deaths accounting 19.4% of the total deaths per year, worldwide ( World Health Organization. Lyon, France: International Agency for Research on Cancer; Feb 3, 2014. Press Release No. 224. Available at: http://www.iarc.fr/en/media-centre/pr/2014/pdfs/pr224_E.pdf). In 2017, it is estimated that 1,55,870 deaths occurred due to Lung cancer, accounting for 1 in 4 of all cancer deaths (American Cancer Society. Cancer facts & Figures 2017). In India, lung cancer constitutes 6.9% and 9.3% of cases & deaths respectively from all cancer related deaths in both sexes. Lung cancer classified into two main types, small-cell lung carcinoma (SCLC) and non-small- cell lung carcinoma (NSCLC), accounting for 15% and 85%, respectively ( Sher T et ah, Mayo Clin Proc 2008;83:355-67. 10.4065/83.3.3554). NSCLC is further classified into three types: squamous-cell carcinoma, adeno carcinoma, and large-cell carcinoma, in which frequency of EGFR mutations can range from 5-17%.
Over 30 years of intensive research by several investigators, has led to major advancement in the treatment of NSCLC which includes surgery, radiation, chemotherapy, targeted therapy and immunotherapy either alone or in combination. Irrespective of the treatment strategies used, only 5% of the patients have shown maximum upto 5-year survival rate and 35% of the patients with wild type tumors have shown only 1-year survival rate (DeSantis CE et ah, 2014. CA Cancer J Clin 2014; 64: 252-71).
Approximately 40% to 80% of NSCLCs, is due to over expressed Epidermal Growth Factor Receptor (EGFR) (Charles N. Prabhakar (2015) Epidermal growth factor receptor in non small cell lung cancer, Transl Lung Cancer Res. 2015 Apr; 4(2): 110-118). The epidermal growth factor receptor (EGFR) is a transmembrane protein and acts as a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands such as Epidermal Growth Factor (EGF), Transforming Growth Factor (TGF), heparin binding growth factor etc. Though, the exact role of EGF on EGFR is completely unknown, it seems that EGFR together with ligands (EGF), specifically regulates the cellular growth. Due to mutations in EGFR, it triggers inappropriate activation and promotes the uncontrolled cell growth (Avraham R et al., Nat Cancer Mol Cell Biol 2011; 12:104-17.), which in turn results into poor prognosis, lower survival, and resistance to therapy (Hirsch FR et al., J Clin Oncol 2003 ;21: 3798-807).
One of the approaches to reduce, the uncontrolled growth is to reduce the availability of EGF to EGFR, by producing high titer anti-EGF antibodies against autologous huEGF. In this approach, available EGF in serum binds to anti-EGF antibodies raised against EGF based therapeutic vaccine, thereby it decreases the binding of EGF to the receptor (EGFR), which further prevents the cell proliferation. However, the inherent problem associated with making an anti-EGF based vaccine lies in the fact that it is autologous and present in the human biological system and therefore no anti-EGF antibody (Ab) response is possible. Hence, to prepare an EGF based vaccine formulation, the selection of a carrier protein(s) is essential so that the EGF breaks the self-tolerance and gets recognized as a vaccine antigen by the immune system. Hence, EGF based therapeutic vaccine made, which elicits antibodies against EGF, that blocks EGFR, so as to prevent cell growth and to treat lung cancer. The said therapeutic vaccine is composed of human recombinant EGF conjugated to P64 carrier protein derived from Neisseria meningitidis and emulsified in Montanide ISA51 (US 2013/0039940 Al; US
2010/0196412 Al). Early trials with this EGF-P64 based vaccine (commercially termed as ‘dMAVAX-EGF’) did show an improved survival rate to some extent in vaccinated subjects, wherein a direct correlation was established between the proportion of antibodies raised in a patient and survival thereof. {Rodriguez, P. C.; Rodriguez, G.; Gonzalez, G. ; Lage, A. (2010). "Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non- small-cell lung cancer therapy". MEDICC Review. 12 (1): 17 23. PMID 20387330).
However, the problem with the chemical conjugation approach may results in a heterologous conjugation mixture. The yield of final purified homogenous mixture could be less and thereby it may not be feasible to meet the demands of multiple dose requirements to treat cancer patients as well as to produce the vaccine commercially.
Therefore, in the present invention, EGF based chimeric proteins were generated using recombinant DNA technology, using immunopotentiator, flagellin as a carrier protein, which can not only enables human epidermal growth factor to be recognized by the human immune system, but also can acts as an innate immune modulator after binding to TLR5 (Toll Like Receptor 5), present on the Immune cells. Moreover, TLR5 have been demonstrated to possess anti-cancer properties along with the ability to enhance immune response compared to other TLRs or NLRs or CLRs. Specifically, Toll Like Receptor 5 (TLR5) agonists are favourably positioned as potential systemic immunotherapeutic agents because of unusual tissue specificity of expression, uniquely safe profile of induced cytokines, and antitumor efficacy demonstrated in a number of animal models (Li-Fen Lee et al., J Immunol 2000, 164: 2769-2775; Sang Hoon Rhee et al., Gastroenterology 2008, 135:518-528.). In addition to it, newer adjuvants in combination with the vaccine antigen may also be desirable.
Furthermore, as a part of cancer treatment, it is also suggested to replace systemic chemotherapeutic treatments with specific target-based therapies in combination with a therapeutic vaccine against lung cancer. Inventors of the present invention describe the use of recombinant chimeric protein of human epidermal growth factor and its vaccine composition with or without adjuvants as a therapeutic vaccine. The vaccine has been tested in a mice tumor model and proved that vaccine composition slows down the progression of a tumor, while increasing the survival period for at least 1 week. Further, this invention also discloses that the use of vaccine composition, immediately after 1 cycle of TKI (tyrosine kinase inhibitor-based EGFR targeted therapy) treatment, increased survival rate by 30% in tumor
induced mice model. Hence, the inventors of this patent application have generated a chimeric protein comprising human recombinant EGF and full length or truncated flagellin protein, that is expressed in E. coli wherein, flagellin tends to impart both adjuvant activity along with anti-tumorigenic activity to the said chimeric protein of recombinant human epidermal growth factor. Flagellin is a bigger molecule by itself and chimeric attachment of flagellin to human epidermal growth factor as a single molecule enables the human immune system to recognize EGF as a foreign vaccine antigen and thereby generates anti-EGF antibodies to treat non small cell lung cancer in humans.
OBJECTIVES OF THE INVENTION
An important objective of this invention is to generate chimeric protein comprising autologous huEGF, so as to produce anti-EGF antibodies against huEGF.
The object of the present invention is to provide anti-EGF antibodies (antibodies against autologous human growth factor), to make EGF (human growth factor) less available for the EGFR to bind and thereby to prevent cell proliferation.
Another object of the present invention is to provide more effective methods of vaccine preparation through the use of autologous growth factor by using an effective carrier protein and by increasing the number of copies of growth factor or EGF, by which immune system is able to recognize huEGF as an immunogen and stimulate immune cells to produce anti-EGF antibodies.
Yet another objective of the invention is to identify new carrier protein which has immunopotentiating property or adjuvant property for the purpose of generating chimeric protein in fusion with human EGF protein.
One of the objectives of the present invention is to generate chimeric proteins containing EGF and full length or truncated flagellin protein, which function both as a carrier protein & immunopotentiator.
Another objective is also to increase the anti-EGF antibodies, by increasing the number of EGF copies in chimeric fusion.
Another objective of the present invention is to evaluate adjuvant and anti-tumorigenic activity of flagellin or fusion proteins containing full length or truncated flagellin.
Yet another objective of the invention is to provide a vaccine composition with or without adjuvant(s) or any applicable delivery system for prophylaxis and/or therapeutic treatment against non-small cell lung cancer wherein EGF is to be used as a vaccine antigen through chimeric approach with novel immunopotentiators.
Another objective of the invention is to determine the efficacy of the chimeric protein as a therapeutic vaccine, while increasing the survival rate.
Additionally, it is also the objective of the present invention to enable combination of targeted therapies to treat non-small lung cancer along with the therapeutic vaccine of the present invention negating the use of systemic chemotherapeutic drugs.
SUMMARY OF THE INVENTION
The present disclosure is directed towards the construction, expression, purification and the characterization of the recombinant chimeric proteins and their respective methods to assess or evaluate the functional properties. Further, the present invention also discloses therapeutic methods of using the recombinant chimeric proteins to treat chronic diseases, such as, for example, lung, breast, head and neck, bladder, prostate, ovarian, vulva, colonic, colorectal, intestinal, pulmonary, brain, oesophagal and other cancers, in which EGF plays an important role to promote cell growth.
In an illustrative embodiment, the recombinant chimeric protein is an immunogenic protein molecule comprising one or more sequences that fold into one physical structure that exposes desired epitopes. For example, chimeric protein expressing full length or truncated sequence of a carrier protein and expressing one or more copies or sequences of autologous human epidermal growth factor or alternate self antigens and thereof that induces high titer anti growth factor or anti-EGF antibodies, after being accessible to cells of the immune system. It is contemplated within the scope of the disclosure that growth factors may be selected from human origin and the said sequence can contain functional parts thereof.
In these illustrative embodiments, the sequence of human growth factors or the alternate self antigens are codon optimized for better expression in E. coli and they are genetically synthesized.
In these illustrative embodiments, the expression of one or more copies or sequence of the growth factor(s) can be present at different positions within the sequence of the recombinant chimeric protein, for example, one copy of growth factor present at N-terminus or C- terminus of the carrier protein and another copy of the growth factor have been positioned at the centre of the flagellin, by replacing the hyper variable regions (D2 & D3), or at N- or C- terminus or in place of D3 region itself.
In an illustrative embodiment, the sequence of the growth factor may include a sequence of one or more of the following growth factors, and/or alternative self-antigens such as, but not limited to, EGF, IGF-1, IGF-2. FGFs 1-23, TGF-a, TGF-b, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EGF, HGF and IFs 1-7.
In other illustrative embodiments, the sequence of carrier protein may include full length or truncated flagellin and it is synthetic in origin, either taken from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or y-protcohactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
In the present disclosure, the resultant chimeric protein may be a single polypeptide expressing a one or more copies of growth factor or self antigens thereof within the sequence of the carrier protein. In an illustrative embodiment, the sequence of the recombinant protein expresses both huEGF and full length or truncated flagellin and presents the EGF on a surface of the recombinant protein, as it was recognized by the anti-EGF antibodies via western blot technique.
Further embodiment of the invention describes the method of protein purification comprising cell lysis, denaturation & refolding followed by self-cleavage due to temperature & pH shift, subsequently, further purification techniques such as ion exchange chromatography, size exclusion chromatography or affinity chromatography via chitin binding domain resin or
Hydrophobic interaction chromatography or chromatography technique using mixed mode resins etc.
It further illustrates the evaluation of adjuvant property, anti-tumorigenic property of carrier protein i.e full length or truncated flagellin of chimeric protein, by in-vitro assays. Further, it also illustrates the characterization of chimeric protein in terms of molecular weight, EGF site recognition and stability.
The further embodiments of the invention also established that the immunogenicity of the chimeric proteins in C57BL/C mice. The protein sequences of SEQ IDs 6 to 10 and 16 to 17 containing nucleic acid sequences, SEQ ID Nos. 1 to 5, 11 and 12 are capable to generate anti-EGF antibodies.
In further embodiment, specific vaccine formulations comprising chimeric proteins with immunomodulator or delivery system have also been made available as one of the embodiments of the present invention optionally in presence of other stabilizers like polyols, sugars such as trehalose or amino acids or combinations.
In one aspect of the invention, there is provided a vaccine composition for immunotherapy against cancer, comprising:
a) vaccine antigen selected from a chimeric protein or construct;
b) adjuvants;
c) stabilizers; and
d) a physiologically acceptable buffer selected from phosphate and citrate.
In some embodiment, the vaccine composition of the present invention comprises the vaccine antigen comprising one or more of the chimeric protein sequences as represented by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2).
In some other embodiment, the vaccine composition of the present invention comprises chimeric protein as vaccine antigen obtained from a codon optimized gene sequences comprising one or more of as represented by SEQ ID No. 1. (EGFL), SEQ ID No. 2 (E1FS1),
SEQ ID No. 3 (E1FS2), SEQ ID No. 4 (E2FS1), SEQ ID No. 5 (E2FS2), SEQ ID No. 11 (BsE2FSl) or SEQ ID No. 12 (EGFL2).
In some embodiment, the vaccine composition of the present invention comprises chimeric protein as vaccine antigen, which comprises of growth factor linked to N-terminal or C- terminal or middle of the full length or truncated carrier protein and is genetically synthesized. In some embodiment of the invention, the chimeric protein is expressed in prokaryotic expression system through a prokaryotic expression plasmid. In some embodiment of the invention, the growth factor is human EGF. In some embodiment of the invention, the human EGF epitopes are exposed on the surface of the chimeric proteins.
In some other embodiment, the composition of the present invention comprises genetically synthesized full length Flagellin protein as carrier protein. In some other embodiment, the carrier protein in the vaccine composition of the present invention is a genetically synthesized truncated Flagellin protein without the hypervariable region which are from amino acid numberl78 to amino acid number 405. In some embodiment of the invention, the genetically synthesized sequence is selected from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g— protcobactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
In some embodiment, the carrier protein the vaccine composition of the present invention helps the immune system to recognize autologous EGF to induce immune response against EGF and acts as adjuvant to enhance Th2 responses or B cell mediated immune responses.
In some embodiment, the adjuvant present in the composition of the invention is selected from one or more of a group of aluminium salt such as aluminium phosphate or aluminium hydroxide, squalene based adjuvants such as MF59, montanide, RIBI adjuvant, incomplete Freund's, glucans, oil-in-water emulsion, MPL, muramyl dipeptide, muramyl dipeptide derivatives, agonists of TLRs (TLR1 to TLR 13) such as MPL, MDP, Imiquimod, poly (I:C), CpG oligonucleotides, Non-CpG oligonucleotides, saponins such as QS-1, ISCOM, ISCOMATRIX, vitamins or immunomodulants such as cytokines, IL-12, IL-15 etc.
In some embodiment, the stabilizer used in the composition of the present invention is selected from the group comprising one or more of sugar such as 5-40% Trehalose or sugar alcohols such as 5-40% Glycerol or 5-40% Sorbitol.
In some embodiment, the vaccine composition according to invention comprises vaccine antigens of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) expressed in E.Coli using the pTWINl plasmid and purified proteins by self cleavage, by temperature from 50-65°C and pH shift ranges from pH 6.5 to 7.5.
In some embodiment, there is provided a method of isolation and purification of proteins of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl), SEQ ID No. 17 (EGFL2), SEQ ID No. 18 (FliC), SEQ ID No. 19 (SDM) or SEQ ID 20 (EGF) comprising the following steps:
i. introducing the recombinant expression plasmid into bacterial host cells in high cell density growth media;
ii. isolation of protein either in the form of insoluble protein from inclusion bodies or in the form of soluble protein;
iii. purification of proteins by at least one or two of the following methods: ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction column chromatography.
In some embodiment, the high cell density growth media as used for isolation and purification of chimeric proteins in the claimed invention comprises 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgS04, 1M CaCh, Biotin, Thiamine and ampicillin.
In some embodiment of the invention, there are provided vaccine composition comprising the chimeric protein sequence as disclosed in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) which are at least 90% - 96% pure.
In another aspect of the invention there is provided a method of treatment to regulate the tumor growth or to increase the survival rate, comprising therapeutic vaccine composition according to invention with or without Tyrosine Kinase Inhibitors (TKIs). In some embodiment, the Tyrosine Kinase Inhibitor comprises 1st or 2nd or 3rd generation TKIs such as Geftinib, Erlotininb, Afatinib, Dacomitinib, Avitinib, Olmutinib or Nazartinib.
In some embodiment, the vaccine composition according to the present invention is stable for at least 2 years at 2-8°C and up to 1 to 72 weeks at 37°C.
In another aspect of the invention, there are provided vaccine composition with immunogenic molecule, a synthetic construct selected from the recombinant chimeric protein sequences as represented in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2); (b) adjuvants, either immunomodulator or delivery system and (c) stabilizers, wherein the said vaccine composition is stable for at least 2 years at 2-8 °C and 1 to 2 weeks at 37°C.
In a further illustrative embodiment, a process for treating a tumor induced mouse model is disclosed. In this illustrative embodiment, the process includes administering therapeutic vaccine, which contains growth factor & pharmaceutically acceptable carrier protein that shows an adjuvant property to promote an immune response. Further, it also discloses the use of tyrosine kinase inhibitor, as a first line treatment followed by therapeutic vaccination to treat tumor induced mouse model.
BRIEF DESCRIPTIONS OF FIGURES
Figure 1: Protein expression, purification and characterization of EGFL.
Figure 1A: depicts SDS-PAGE of EGFL chimeric protein expressed in BL21 cells, induced with IPTG.
Figure IB: represents EGFL (before and after cleavage) and its purified elution fractions by ion-exchange chromatography.
Figure 1C: elucidates characterization of EGFL (before and after cleavage) by western blot using Human Anti-EGF antibody.
Figure ID: shows purified EGFL by Size Exclusion chromatography.
Figure IE: shows purified protein EGFL by affinity chromatography using CBD (chitin binding domain) resin.
Figure IF : depicts the yields of EGFL protein tested in different media.
Figure 2A: SDS-PAGE gel depicts the expression of E1FS1 (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
Figure 2B: elucidates characterization of E1FSI (before and after cleavage) by western blot using Human Anti-EGF antibody.
Figure 2C: SDS-PAGE gel depicts the expression of E2FS1 (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
Figure 2D: elucidates characterization of E2FS1 (before and after cleavage) by western blot using Human Anti-EGF antibody.
Figure 2E: SDS-PAGE gel depicts the expression of FliC (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
Figure 2F: SDS-PAGE gel depicts the expression of SDM (refolded, before cleavage) and its self cleaved target protein (after cleavage) and its purified elution fractions both by ion- exchange chromatography followed by SEC.
Figure 2G: illustrates western blot representing the E. coli expressed recombinant huEGF, recognized by the vaccinated sera raised against EGFL.
Figure 3A: illustrates a bar graph quantification of exposed EGF epitopes in its conformational form of EGFL or E1FS1 or E2FS1 chimeric proteins, anti-EGF antibody using huEGF quantification kit.
Figure 3B: illustrates a bar graph of anti-FliC antibody binding to recombinant full length FliC or truncated flagellin (SDM) or EGFL or E1FS1 or E2FS1 proteins that were captured on to ELISA plates.
Figure 4A: illustrates dose response curve generated by EGFL activity as an immunopotentiator, when stimulated with HEK Blue reporter cells engineered with TLR5.
This figure represents dose response curve generated by EGFL activity as an immunopotentiator, when stimulated with HEK Blue reporter cells that were engineered with TLR5. Flagellin (FliC) was taken as a positive control. In graph, X-axis represents concentration of protein in log scale and Y-axis represents % response of protein. Each data set point is represented as a Mean+SD, which was obtained from three independent experiments done in duplicates.
Figure 4B: illustrates dose response curve generated by E1FS1 & E2FS1 activity as an immunopotentiator, when stimulated with HEK Blue reporter cells engineered with TLR5. This figure represents dose response curve generated by E1FS1 & E2FS1 activity as an immunopotentiator, when stimulated with HEK Blue reporter cells that were engineered with TLR5. Truncated Flagellin (SDM) was taken as a control. In graph, X-axis represents concentration of protein in log scale and Y-axis represents % response of protein. Each data set point is represented as a Mean+SD, which was obtained from three independent experiments done in duplicates.
Figure 4C: The graph shows secreted IL-8 cytokine by EGFL, by stimulating genetically engineered HEK Blue reporter cells with TLR5 gene. EGFL secreted approximately 700pg/ml IL-8 cytokine, whereas FliC secreted 200pg/ml. Secretion of IL-8 by TLR5 activated cells indicated anti-tumorigenic properties exhibited by EGFL.
Figure 5: Anti cell prolification growth pattern of NCI-H1975 cells, when treated with (Figure 5A): vaccinated sera against raised against EGFL, E1FS1, E2FS1, FliC and SDM (purified commercial anti-EGF antibody used as positive control); and (Figure 5B): combination of Geftinib and vaccinated sera against EGF, EGFL, E1FS1, E2FS1, FliC and SDM.
Figure 6A: Antibody titer raised against chimeric EGFL in mice.
Figure 6B: ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing EGFL.
Figure 6C: ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing E1FS1.
Figure 6D: ELISA assay to represent EGF specific endpoint titer elicited against immunogenic composition containing E2FS1.
Figure 6E: represents Thl:Th2 index of anti-EGF isotype antibody elicited against chimeric proteins.
Figure 7A: ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing EGFL
Figure 7B: ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing E1FS1
Figure 7C: ELISA assay to represent flagellin specific antibody elicited against immunogenic composition containing E2FS 1
Figure 8A: ELISA assay to represent EGF specific endpoint titer elicited against EGFL, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants. X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
Figure 8B: ELISA assay to represent EGF specific endpoint titer elicited against E1FS1, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants. X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
Figure 8C: ELISA assay to represent EGF specific endpoint titer elicited against E2FS1, when mice were vaccinated with 50 pg EGFL/mouse with or without adjuvants. X-axis indicates vaccinated mice sera dilution and Y-axis represents absorbance at 490 nm.
Figure 9: Determination of tumor growth pattern induced by two different cell densities of LLC1 (Lewis Lung Cancer Cell line) in mice at different time points, so as to assess the ideal cell density to generate mice tumor model for therapeutic vaccination. This graph shows that mice started developing tumor from Day 7 onwards. Mice that received lxlO6 cells/mouse, shown rapid tumor development, whereas mice that received 0.2xl06 cells/mouse have shown slow tumor growth. Hence, to generate proof of concept study of therapeutic vaccination by EGFL, high cell density was selected to generate mice induced tumor model.
Figure 10A: Represents rate of tumor growth before and after treatment. X-axis indicates day on which tumor was measured and Y-axis indicates tumor volume. Tumor size increased drastically in mice after receiving tumor cells upto day 17, thereafter, slow tumor growth was observed immediately after receiving vaccination.
Figure 10B: Anti-EGF antibody response and EGF levels in serum are very well correlated thus proving immuno therapeutic activity of chimeric EGFL.
Figure 11: illustrates the survival graphs of tumor induced mice when treated with EGFF (as depicted in Figure 11A), E1FS1 (as depicted in Figure 11B), and E2FS1 (as depicted in Figure 11C). Further Figure 11D, Figure HE, and Figure 11F represents tumor induced mice treated with EGF, FliC and SDM respectively used as control.
Figure 12: Depicts survival rate of mice treated with Geftinib alone (Figure 12A) and in combination with EGFF (Figure 12B).
DETAILED DESCRIPTION OF THE INVENTION
Detailed embodiments of the present recombinant chimeric proteins or vaccines are disclosed herein, however, it is to be understood that the disclosed embodiments are merely exemplary, which may be embodied in various forms. Therefore, specific functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the recombinant protein disclosed herein.
The present disclosure provides a construction of recombinant chimeric protein expressing full length or truncated flagellin and a human epidermal growth factor (EGF) is described. Further, in one illustrative embodiment, construction of recombinant chimeric protein comprising one or more copies of growth factor to improve the presentation of the maximum number of growth factor epitopes. It is contemplated within the scope of the disclosure that such recombinant chimeric proteins are highly immunogenic to the human immune system. Preferably, the recombinant proteins confer additional properties to the chimeric protein, for example, high expression yield and ease of manufacture and stability.
According to the disclosure the recombinant proteins, whether one or more copies of growth factor fused with either full length or truncated flagellin elicits broad range of immune responses against EGF (epidermal growth factor). Hence, these EGF based chimeric proteins may be useful in treating chronic diseases, for example, breast, lung, bladder, ovarian, Vulva, colonic, pulmonary, brain, colorectal, intestinal, head and neck, and esophagus cancers, where, EGF is responsible for uncontrolled cell proliferation.
The present invention discloses construction of codon optimized chimeric genes and its expression, purification & characterization. Chimeric gene encodes Epidermal Growth Factor
(EGF) and a full length or truncated flagellin (without hypervariable region, from the position 178 to 405 amino acids). The present invention also describes the function of the flagellin both as an adjuvant and anti-tumorigenic property. In another embodiment, the present invention also discloses that the purified chimeric protein was able to elicit high titer antibodies against EGF in C57BL/6 mice and also substantially increased survival rate, by reducing the tumor progression rate.
In one aspect of the invention, there is provided a vaccine composition for immunotherapy against cancer, comprising:
a) vaccine antigen selected from a chimeric protein or construct;
b) adjuvants;
c) stabilizers; and
d) a physiologically acceptable buffer selected from phosphate and citrate.
In some embodiment, the vaccine composition of the present invention comprises the vaccine antigen comprising one or more of the chimeric protein sequences as represented by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2).
In some other embodiment, the vaccine composition of the present invention comprises chimeric protein as vaccine antigen obtained from a codon optimized gene sequences comprising one or more of as represented by SEQ ID No. 1. (EGFL), SEQ ID No. 2 (E1FS1), SEQ ID No. 3 (E1FS2), SEQ ID No. 4 (E2FS1), SEQ ID No. 5 (E2FS2), SEQ ID No. 11 (BsE2FSl) or SEQ ID No. 12 (EGFL2).
In some embodiment, the vaccine composition of the present invention comprises chimeric protein as vaccine antigen, which comprises of growth factor linked to N-terminal or C- terminal or middle of the full length or truncated carrier protein and is genetically synthesized. In some embodiment of the invention, the chimeric protein is expressed in prokaryotic expression system through a prokaryotic expression plasmid. In some embodiment of the invention, the growth factor is human EGF. In some embodiment of the invention, the human EGF epitopes are exposed on the surface of the chimeric proteins.
In some other embodiment, the composition of the present invention comprises genetically synthesized full length Flagellin protein as carrier protein. In some other embodiment, the carrier protein in the vaccine composition of the present invention is a genetically synthesized truncated Flagellin protein without the hypervariable region which are from amino acid numberl78 to amino acid number 405. In some embodiment of the invention, the genetically synthesized sequence is selected from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g— protcobactcria such as Salmonella typhimurium or Enterica species or b-proteobacteria such as Bordetella.
In some embodiment, the carrier protein the vaccine composition of the present invention helps the immune system to recognize autologous EGF to induce immune response against EGF and acts as adjuvant to enhance Th2 responses or B cell mediated immune responses.
In some embodiment, the adjuvant present in the composition of the invention is selected from one or more of a group of aluminium salt such as aluminium phosphate or aluminium hydroxide, squalene based adjuvants such as MF59, montanide, RIBI adjuvant, incomplete Freund's, glucans, oil-in-water emulsion, MPL, muramyl dipeptide, muramyl dipeptide derivatives, agonists of TLRs (TLR1 to TLR 13) such as MPL, MDP, Imiquimod, poly (I:C), CpG oligonucleotides, Non-CpG oligonucleotides, saponins such as QS-1, ISCOM, ISCOMATRIX, vitamins or immunomodulants such as cytokines, IL-12, IL-15 etc.
In some embodiment, the stabilizer used in the composition of the present invention is selected from the group comprising one or more of sugar such as 5-40% Trehalose or sugar alcohols such as 5-40% Glycerol or 5-40% Sorbitol.
In some embodiment, the vaccine composition according to invention comprises vaccine antigens of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) expressed in E.Coli using the pTWINl plasmid and purified proteins by self cleavage, by temperature from 50-65°C and pH shift ranges from pH 6.5 to 7.5.
In some embodiment, there is provided a method of isolation and purification of proteins of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl), SEQ ID No. 17 (EGFL2),
SEQ ID No. 18 (FliC), SEQ ID No. 19 (SDM) or SEQ ID 20 (EGF) comprising the following steps:
i. introducing the recombinant expression plasmid into bacterial host cells in high cell density growth media;
ii. isolation of protein either in the form of insoluble protein from inclusion bodies or in the form of soluble protein; and
iii. purification of proteins by at least one or two of the following methods: ion exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction column chromatography.
In some embodiment, the high cell density growth media as used for isolation and purification of chimeric proteins in the claimed invention comprises 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgSCC, 1M CaCh, Biotin, Thiamine and ampicillin
In another aspect of the invention, vaccine composition provided with immunogenic molecule, a synthetic construct selected from the recombinant chimeric protein sequences as represented in by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2); (b) adjuvants, either immunomodulator or delivery system and (c) stabilizers, wherein the said vaccine formulation is stable for at least 2 years at 2-8 °C and 1 to 2 weeks at 37°C.
In some embodiment of the invention, the vaccine composition comprises chimeric protein sequence as disclosed in SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS 1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS 1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FS l) or SEQ ID No. 17 (EGFL2) which are at least 90% - 96% pure.
In another aspect of the invention there is provided a method of treatment to regulate the tumor growth or to increase the survival rate, comprising therapeutic vaccine composition according to invention with or without Tyrosine Kinase Inhibitors (TKIs). In some embodiment, the Tyrosine Kinase Inhibitor comprises 1st or 2nd or 3rd generation TKIs such as Geftinib, Erlotininb, Afatinib, Dacomitinib, Avitinib, Olmutinib or Nazartinib.
In some embodiment, the vaccine composition according to the present invention is stable for at least 2 years at 2-8°C and up to 1 to 2 weeks at 37°C.
EXAMPLES
The invention will now be further illustrated with reference to the following examples.
Recombinant chimeric proteins were created expressing the entire EGF coding region on the full length or truncated flagellin at either at the N or C-terminus or in place of hypervariable D2 & D3 domains or D3 region of flagellin. Chimeric gene constructs containing autologous EGF, either at N- or C-terminal or within the sequence of full length or truncated flagellin. Flagellin in synthetic chimeric protein may contain protein sequence similar to flagellin sequence from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile or g-proteobacteria such as Salmonella typhimurium or enterica species or b-proteobacteria such as Bordetella. Construction of each chimeric genes of the present invention is as detailed in examples 1.1 to 1.8
In the illustrative embodiments given below, include EGF fused to full length or truncated flagellin either at N- or C- termini of the full length or truncated flagellin with the help of linkers. Additional recombinant EGF is again fused either at N- or C-termini or at the middle of the full length flagellin by restriction enzyme. The addition of the linkers can reduce steric hindrance and may also enable unique restriction sites to be introduced within the linkers to allow subsequent manipulation of the genetic constructs. To generate the following constructs given below, amino acid linkers were used, but not limited to EAAAKP, AS and AAA.
Example 1: Generation of the plasmid encoding chimeric constructs:
All chimeric constructs were first cloned into pUC57 plasmid and then further cloned into pTWINl expression plasmid. To generate these various chimeric constructs, synthetic FC- EGFF gene sequence, which was cloned into pUC57 (as pUC57 FC_EGFF or pUC57EGFFWO) was taken as a starting plasmid.
To generate library of EGF based chimeric constructs, pTWINl (7375 base pairs, New England Biolabs, Cat#N6951S), a derivative of pBR322 plasmid was used as an E.coli
expression vector. Plasmid pTWINl express the target gene, under the control of T7 promotor, which is regulated by IPTG or Lactose due to the presence of Lac I gene. The purpose of using the pTWIN 1 vector is due to its advantage of controllable self cleavage of modified Sap DnaB (Mathy, S et al., (1999) Gene. 231, 1-13) at the N-terminus target protein or thiol induced cleavage of Mxe GyrA inteins (Evans, T.C et al., (1998) Protein Sci. 7, 2256- 2264; Southworth, M.W et al., (1999) BioTechniques. 27, 110-120) at the C-terminus target protein. Further, the presence of the chitin binding domain from Bacillus circulans (Chong, S., et al., (1997) Gene. 192, 271-281; Watanabe, T et al., (1994) J. Bacteriol. 176, 4465-4472) facilitates purification without any use of protease, unlike using tags like His etc.
Example 1.1: Construction of plasmid encoding EGFL_Nucleic acid sequence of EGFL includes autologous human EGF at N-terminus of full length flagellin and these two sequences are connected by a linker. The whole gene comprising of 1698bps (Seq ID No. 1) and the corresponding translated protein sequence (SEQ ID No. 6) contains 565 amino acids with a molecular weight of approximately 62 kDa.
EGFL was amplified by PCR from pUC57-LC-EGFL (which was genetically synthesized sequence from Genscript) using appropriate primers to introduce Sapl site at the N-terminus of EGFL. This PCR fragment, digested with Sapl & Pstl restriction enzymes and was ligated into pUC57 & pTWIN 1 vectors and named as pUC57 EGFLWO & pTWIN 1 EGFL respectively. Further, plasmid pTWINl encoding EGFL was transformed into DH5alpha. Single cell colonies were selected from the plate containing 100 pg/mL ampicillin, grown overnight at 37 °C. These clones were screened by restriction digestion and confirmed by nucleotide sequencing using the appropriate sequencing primers.
Example 1.2: Construction of plasmid encoding E1FS1 Nucleic acid sequence of E1FS1 consists of autologous human EGF at N-terminus of truncated flagellin with deletion of hypervariable region D2 & D3 region (amino acids from position 178 to 405aas). E1FS1 gene sequence was generated by deleting hypervariable regions D2 & D3 from EGFL by site directed mutagenesis. The whole gene comprising of 1017bps (Seq ID No. 2) and the corresponding translated protein sequence (SEQ ID No. 7) contains 338 amino acids with a molecular weight of approximately 37 kDa.
To generate Plasmid pUC57-ElFSl, hypervariable region (position 178 to 405aas) of flagellin was deleted from pUC EGFL (WO), using appropriate primers and purified the circularized plasmid containing E1FS1, after Dpn digestion. E1FS1 fragment from pUC57 was digested with Sapl & Pstl, and ligated into pTWINl vector. After transformation into DH5alpha, clones were screened by restriction digestion and confirmed by DNA sequence using appropriate sequencing primers.
Example 1.3: Construction of plasmid encoding E1FS2 Nucleic acid sequence of EFS2 consists of autologous human EGF at N-terminus of truncated flagellin with deletion of hypervariable region D3 region (amino acids from position 186 to 285aas). E1FS2 gene sequence was generated by deleting hypervariable regions D3 from EGFL by site directed mutagenesis. The whole gene comprising of 1401bps (Seq ID No. 3) and the corresponding translated protein sequence (SEQ ID No. 8) contains 466 amino acids with a molecular weight of approximately 51 kDa.
To generate Plasmid pUC57-ElFS2, where hypervariable region D3 (position 186 to 285aas) of flagellin was deleted from pUC EGFL (WO), using appropriate primers and purified the circularized plasmid containing E1FS2, after Dpn digestion. E1FS2 fragment from pUC57 was digested with Sapl & Pstl, and ligated into pTWINl vector using the same restriction sites. After transformation into DH5alpha, clones were screened by restriction digestion and confirmed by DNA sequence using appropriate sequencing primers.
Example 1.4: Construction of plasmid encoding E2FS1 Nucleic acid sequence of E2FS1 consists of 2 copies of autologous human EGF and truncated flagellin with deletion of D2 & D3 region. E2FS1, wherein, 1 copy of EGF located at N-terminus and another copy located within the sequence of the flagellin (in place of D2 & D3 region). E2FS 1 gene sequence was generated by introducing second copy of EGF into E1FS1 using Nhel site as linker. The whole gene comprising of 1185bps (Seq ID No. 4) and the corresponding translated protein sequence (SEQ ID No. 9) contains 394 amino acids with a molecular weight of approximately 43 kDa.
To generate E2FS1, plasmid pUC57-ElFSl was digested with Nhel and used as a vector after gel purification. The second copy of EGF insert, which was amplified from the pUC EGFL (WO or the previous one) with Nhel sites at both N- & C-terminus using appropriate primers
was ligated. After ligation, E2FS1 was inserted into pTWINl plasmid using Sapl & Pstl from pUC57-E2FSl. Clones were screened by restriction digestion and confirmed by nucleotide sequencing using appropriate primers.
Example 1.5: Construction of plasmid encoding E2FS2 Nucleic acid sequence of E2FS2 consists of 2 copies of autologous human EGF and truncated flagellin with deletion of D3 region. E2FS2, wherein, one copy of EGF located at N-terminus and another copy located within the sequence of flagellin (in place of D3 region). E2FS2 gene sequence was generated by introducing second copy of EGF into E1FS2 with the help of Nhel restriction site as a linker. The whole gene comprising of 1569bps (Seq ID No. 5) and the corresponding translated protein sequence (SEQ ID No. 10) contains 522 amino acids with a molecular weight of approximately 57 kDa. The plasmid (pTWINl-E2FS2) was constructed using sapl & pstl restriction enzymes and the plasmid was transformed into DH5a. Single cell positive colonies were selected from the plate containing 100 pg/mL ampicillin grown overnight at 37°C. These positive colonies were further confirmed by nucleotide sequencing.
Example 1.6: Construction of plasmid encoding BsE2FSl: Nucleic acid sequence of BsE2FSl consists of 2 copies of autologous human EGF and flagellin derived from Bacillus subtilis (strain 168), wherein, 1 copy of EGF located at N-terminus and another copy at the C- terminus of flagellin. The whole gene comprising of 1260bps (Seq ID No. 11) and the corresponding translated protein sequence (SEQ ID No. 16) contains 420 amino acids with a molecular weight of approximately 46 kDa.
BsE2FSl was a synthetic sequence from pUC57 vector was digested with Sapl & Pstl and ligated into Sapl & Pstl digested pTWINl vector. After ligation, Plasmid pTWINl encoding BsE2FSl was transformed into DH5alpha and positive clones were screened by restriction digestion and confirmed by nucleotide sequencing done using appropriate primers.
Example 1.7 - Construction of plasmid encoding EGFL2: Nucleic acid sequence of EGFL2 includes 2 copies of autologous human EGF both at N- & C- terminus of full length flagellin and these two sequences are connected by a linker. The whole gene comprising of 1863 bps (Seq ID No. 12) and the corresponding translated protein sequence (SEQ ID No. 17) contains 621 amino acids with a molecular weight of approximately 79 kDa.
To generate EGFL2, second copy of EGF was introduced to full length flagellin at the C- terminus using Nhel site using FW Nh & Rv Pst in pUC57. Further, EGFF2 sequence from pUC57 was digested with Sapl & Pstl and ligated into Sapl & Pstl digested pTWINl vector. After ligation, Plasmid pTWINl encoding EGFF2 was transformed into DH5 alpha and positive clones were screened by restriction digestion and confirmed by nucleotide sequencing done using appropriate primers.
Example 1.8: Construction of plasmid encoding recombinant Full length (FliC) or truncated flagellin: (SDM- deletion of hypervariable region D2 & D3 of flagellin)
Example 1.8a: Nucleic acid sequence of FFiC includes full length flagellin. The whole gene comprising of 1518 bps (Seq ID No. 13) and the corresponding translated protein sequence (SEQ ID No. 18) contains 506 amino acids with a molecular weight of approximately 55 kDa. FliC was amplified by PCR from pUC57-FC-EGFF (genetically synthesized sequence) using appropriate primers. This insert was ligated into Sapl & Pstl digested pTWINl vector. Plasmid pTWINl encoding FliC was transformed into DH5alpha and positive clones were screened by digestion (Pstl & Xbal) and confirmed by DNA sequencing using the appropriate primers.
Example 1.8b: Construction of truncated Flagellin (SDM)_Nucleic acid sequence of SDM EGFF includes truncated flagellin with deletion of hypervariable region D2 & D3 region (amino acids from position 178 to 405aas). The whole gene comprising of 837 bps (Seq ID No. 14) and the corresponding translated protein sequence (SEQ ID No.19) contains 279 amino acids with a molecular weight of approximately 30 kDa.
SDM was amplified from pUC57 E1FS1, clone#5 using appropriate primers. PCR fragment was purified and digested with Sapl & Pstl and used as insert. This insert was introduced into the Sapl & Pstl digested pTWINl by ligation. After ligation, plasmid pTWINl containing SDM was transformed into DH5alpha and positive clones were selected by digestion with Nhel & Pstl and confirmed by sequencing using appropriate primers.
Example 1.9: Construction of plasmid encoding Epidermal Growth Factor (EGF):_Nucleic acid sequence of autologous human EGF comprising of 162bps (Seq ID No. 15) and the
corresponding translated protein sequence (SEQ ID No. 20) contains 54 amino acids with a molecular weight of approximately 6.2 kDa.
Plasmid pTWINl containing EGF was generated by ligating Sapl & Pstl digested pTWINl vector and also PCR amplified EGF from the plasmid that has genetically synthesized sequence of EGF. After ligation, Plasmid pTWINl encoding EGF was transformed into DH5alpha and positive clones were confirmed by digestion (Pstl & Nhel) and sequence was confirmed by DNA sequencing using the appropriate primers. The above mentioned chimeric constructs, which were cloned in pTWINl expression plasmid were used to express the chimeric protein such as (EGFL, E1FS1, E1FS2, E2FS1, E2FS2, BsE2FSl, EGFL2 etc.,) and to evaluate their efficiency as a therapeutic vaccine candidates. Further, pTWINl expression plasmid constructs encoding genes such as [(EGF, full length flagellin (FliC) or truncated Flagellin (SDM)] were also generated to express recombinant proteins such as (EGF, FliC, SDM respectively) and used as controls in both in-vitro and in- vivo studies. A summary is provided as per the below Table 1 for all the Nucleic Acids and recombinant proteins:
TABLE 1: Summary of Recombinant chimeric proteins and Recombinant proteins
Example 2: Expression & Characterization of Chimeric Proteins:
Example 2.1: Expression & Characterization of EGFL: The plasmid (pTWINl-EGFL) was again transformed into E. coli BL21 (DE3) (NEB, Cat#C2527I) or BL21 Rosetta 2 (DE3) pLysS Cat#71401, or Rosetta™ 2 (DE3) competent cells (Novagen, Cat#70954). Single colony was isolated from the LB plate with 100 pg/mL amp and further grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacterial culture was induced with 0.2 - 1 mM IPTG for 16-18 h (as shown in Figure 1A). Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed protein, SDS-PAGE sample buffer was added to the cell pellet and resolved proteins on SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. Further, the gel with expressed protein having MW 85kDa (before cleavage) and 62kDa (after cleavage) was transferred on to a nitrocellulose membrane for a western blot. Mouse anti-hEGF antibody (Abeam, Cat#abl0409) and HRP-labeled goat- anti-mouse IgG were used as primary and secondary antibody respectively. 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate. Western blot analysis determined that the chimeric protein EGFL displays the EGF epitopes in the correct conformation and thus EGFL is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 1C.
In order to increase the EGFL protein yield, BL21 (DE3) cells were grown in different media compositions (PP, LBM9, CYM9 media or enriched media), while testing in different induction protocols, using Lactose as inducer.
PP Media: Single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in PP media composed of 40% glucose, M9 salt solution, trace elements, 1M MgS04, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5. Further it was induced with 0.5% lactose and incubated overnight at 25°C. Cells were finally harvested further processed for protein extraction and purification.
LBM9 media: Single colony was inoculated from a fresh transformed plate into 5 ml of LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in LBM9 media composed of 2% LB media, 40% glucose, M9 salt solution,
trace elements, 1M MgSC , 1M CaCF, Biotin, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5. Further it was induced with 0.5% lactose and incubated overnight at 25°C. Cells were finally harvested by and further processed for protein extraction and purification.
BBIL-CYM9 Media: In this disclosure, bacterial culture was grown in the below mentioned media to obtain high cell density and then induced with lactose to increase the yield. Briefly, single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10 % inoculum was used for secondary culture in CYM9 media composed of 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgSCL, 1M CaCb, Biotin, Thiamine and ampicillin and incubated at 37°C, 250 rpm till the OD reached 6.5. Further it was induced with 0.2% lactose and incubated for 3 hrs at 37°C. From this, again 10% inoculum was used for sub culture in CYM9 media and induced with 0.2% lactose and incubated for overnight at 25°C. Cells were finally harvested and further processed for protein extraction and purification. The present invention also discloses the abovementioned novel media, namely BBIL-CYM9 used with double induction.
Enriched media: Single colony was inoculated from a fresh transformed plate into LB Media and incubated for 16-18 hrs at 37°C, 250 rpm. Then, 10% inoculum was used for secondary culture in enriched media composed of 1.5% yeast extract, 1.5% Casein, 2% glycerol, M9 salt solution, trace elements, 1M MgS04, Thiamine and ampicillin and incubated at 37°C till the OD reaches 0.4-0.6. Culture was then induced with 0.2% lactose and incubated for 3 hrs at 37°C. Induced culture was used as inoculum (10%) for inoculating tertiary culture and incubated at 37°C, 250 rpm till the OD reaches 3. Further it was induced with 0.2% lactose and incubated overnight at 25°C. Cells were finally harvested by centrifugation at highest rpm for 20 minutes and further processed for protein extraction.
The yield of EGFL chimeric protein tested in different media are represented as shown in Table 2 below and the Figure IF represents the data corresponding to the above Table 2.
TABLE 2: Yield of EGF chimeric protein tested in different media
Example 2.2: Expression & Characterization of E1FS1: The plasmid (pTWINl-ElFSl) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37 °C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed protein, SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. The expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) (as shown in Figure 2A). The gel was transferred to a nitrocellulose membrane for a western blot. Mouse anti-hEGF antibody and HRP-labeled goat-anti-mouse IgG were used as primary and secondary antibody respectively. 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate. In this disclosure, Western blot analysis determined that the chimeric protein E1FS1 can display the EGF epitopes in the correct conformation and thus E1FS1 is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 2B.
Example 2.3: Expression & Characterization of E2FS1: The plasmid (pTWINl-E2FSl) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed protein, SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. The expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) (as shown in Figure 2C). The gel was transferred to a nitrocellulose membrane for a western blot. Mouse anti-hEGF antibody and HRP-labeled
goat-anti-mouse IgG were used as primary and secondary antibody respectively. 3,3 - diaminobenzidine tetrahydrochloride (DAB) was used as a substrate. In this disclosure, Western blot analysis determined that the chimeric protein E2FS1 can display the EGF epitopes in the correct conformation and thus E2FS 1 is able to get recognized by the anti-EGF antibodies, as illustrated in Figure 2D.
Example 2.4: Expression & Characterization of FliC: The plasmid (pTWINl-FliC) was again transformed into E. coli BF21 (DE3) competent cells. Single colony was isolated and grown in FB medium containing 100 pg/mF amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed protein, SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. The expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate
Polyacrylamide Gel Electrophoresis) (as shown in Figure 2E).
Example 2.5: Expression & Characterization of SDM: The plasmid (pTWINl-SDM) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 hours. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed protein, SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. The expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate
Polyacrylamide Gel Electrophoresis) (as shown in Figure 2F).
Example 2.6: Expression & Characterization of HuEGF: The plasmid (pTWINl-EGF) was again transformed into E. coli BL21 (DE3) competent cells. Single colony was isolated and grown in LB medium containing 100 pg/mL amp overnight at 37°C with shaking to get start up culture. The culture was then diluted to 1-10% and allowed to grow until the OD600 reached 0.4 - 0.6. Next, the bacteria were induced with 0.2mM IPTG for 16-18 h. Cells were finally harvested by centrifugation at 12,000 rpm for 20 minutes. To check the expressed
protein, SDS-PAGE sample buffer was added to the cell pellet and ran SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) under non-reducing conditions. The expressed protein was characterized by SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis). The gel was transferred to a nitrocellulose membrane for a western blot. Mouse vaccinated sera raised against EGFL was used to probe huEGF as a primary antibody and HRP-labeled goat- anti-mouse IgG was used as secondary antibody. 3,3 -diaminobenzidine tetrahydrochloride (DAB) was used as a substrate.
In this disclosure, Western blot analysis determined that the anti-EGF antibodies raised against EGFL were able to bind to huEGF, as illustrated in Figure 2G.
Example 3: Isolation, purification & characterization of recombinant proteins:
The given illustrative embodiment discloses the isolation and purification protocol for all recombinant proteins that were disclosed in the present invention.
The E. coli culture pellet was resuspended in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 150 mM NaCl, pH 8.5) with lysozyme (1 mg/ml). Then, DNase and MgCF were added with agitation at 4°C. The cell culture was subjected to sonication with conditions (40 amplitude for 10 seconds ON’ & 10 seconds OFF’, later 70 amplitude for 30 minutes with 10 seconds ON’ and 10 seconds OFF’) and after sonication sample was centrifuged at 12000 rpm for 15-20 minutes. Pellet & Supernatant was separated & checked by SDS-PAGE. Protein was found in supernatant in soluble form and the solution was kept at 4°C. This protein solution was dialyzed against cleavage buffer (20 mM Tris-Cl, 2 mM EDTA, 150 mM NaCl, pH 6.0 & 5% glycerol) for 48-72 hours at RT. Temperature (from 4°C to RT) & pH shift (from pH 8.5 to pH range from 6.5 - 7.5) was done to induce Ssp DnaB intein self-cleavage. Finally, the solution was subjected to heat treatment at 50-65°C for 30 minutes and supernatant was collected by centrifugation at 12000 rpm for 10 minutes at 4°C. The supernatant containing desired protein was further subjected to protein purification by ion exchange chromatography (IEC) followed by Size exclusion chromatography (SEC) to achieve higher purity of upto 99% of the targeted protein. Alternatively, higher purity of up to 99% pure protein may also be obtained using either one of the following methods or in combination such as Ion-exchange chromatography or affinity chromatography using CBD (Chitin Binding Domain) resin or
hydrophobic interaction chromatography or Size exclusion chromatography or chromatography using mixed mode resins.
Example 3.1: Ion Exchange Chromatography (IEC): The suspension of heated or cleaved mixture was directly injected into a MacroPrep High Q 3HT strong anion exchange resin obtained from Biorad. Resin was equilibrated with 3 volumes of equilibration buffer pH 6.5 (20 mM Tris, 0.2 mM EDTA, 150 mM NaCl, 0.01 % sodium azide, 0.1 % Tween 20 & 0.1 % Triton X-114). The sample was loaded on to the column with a flow rate 0.5 ml/min. The desired chimeric protein that is devoid of intein CBD tag was collected by elution buffer (20 mM Tris-Cl, 0.2 mM EDTA, 400mM NaCl, pH 7.5) with a flow rate 1 mL/min. Purified IEC fractions of chimeric proteins EGFL, E1FS1 and E2FS1 are illustrated in Figure IB, Figure 2A and Figure 2C respectively and IEC purified recombinant proteins such as FliC, and SDM are illustrated in Figure 2E and 2F respectively.
Example 3.2: Size exclusion chromatography (SEC): Superdex 200 resin packed in XK16/60 column was used to purify the recombinant chimeric protein(s). Initially, column was equilibrated with IOC Vs of equilibration buffer (lxPBS, pH 7.4). Sample was loaded at a flow rate of 0.5 ml/min followed by desired protein elution at a flow rate of 0.8 ml/min. Purified SEC fractions of chimeric proteins EGFF, E1FS1 and E2FS1 are illustrated in Figure ID, Figure 2A and Figure 2C respectively and SEC purified recombinant proteins such as FliC, and SDM are illustrated in Figure 2E and 2F respectively.
Example 3.3: Affinity Chromatography: To remove intein associated chitin binding domain, which was expressed along with chimeric proteins, the affinity column packed with chitin resin was used. The chitin resin was equilibrated with 10 column volumes (CVs) of equilibration buffer (20 mM Tris-Cl, 500 mM NaCl, 1 mM EDTA, 0.1% Tween 20, pH 8.5) followed by sample loading on to the column with a flow rate 0.5 ml/min or less. Column was washed with 10 CVs equilibration buffer. Eater 1 bed volume of cleavage buffer was added and flushed through the column quickly and filled the column with 1CV of cleavage buffer (20 mM Tris-Cl, 1M NaCl, 1 mM EDTA, 0.1% Tween 20, pH 6.5 - 7.5) and allowed to incubate at RT for 24-48 hours. Bound fractions were eluted with 3-5 CVs of cleavage buffer. At each step fractions were collected and analysed by SDS-PAGE. Purified fractions of EGFF using affinity chromatography are illustrated in Figure IE. Protein Yield expressed in FB media with 0.2 mM IPTG induction has been shown in Table 3
Table 3: Protein Yield expressed in LB media with 0.2 mM IPTG induction
Example 4: Quantification & Characterization of functional properties of EGF:
Example 4.1: Determination of EGF epitope binding and its quantification by ELISA:
To demonstrate, whether the chimeric proteins retain the antigenicity or recognition site, in its folded form, Further, to assess the increased level of EGF recognition, especially, in case of recombinant chimeric protein such as E2FS1, where in 2 copies of EGF were fused was estimated by ELISA using Human EGF ELISA kit (Cat# KHG0061, Invitrogen).
Quantification of Human EGF by ELISA: The assay was done as per the instructions given in the manual. Briefly, 96 well plate coated with anti-EGF antibody (capture antibody) was used. Later, Standards, control (EGF) or pre diluted Recombinant protein samples such as EGFL or E1FS1 or E2FS1 or BsE2FSl or EGFL2 (IOOmI of each sample/per well) were added to each well and incubated it for 2 hours. The plate was washed four times with PBS containing 0.5% Tween (PBST). Further, Biotin conjugated anti-Hu EGF antibody (100 mΐ/well) was added and incubated the plate at room temperature for lhr. After washing the plate, 100 mΐ of 1 x streptavidin-HRP conjugate was added and incubated it for 30 minutes. Finally, chromogen (TMB) was used as a substrate. After 30 minutes of incubation, reaction was stopped with stop solution and read the absorbance at 450 nm. These results show that the EGF epitopes of chimeric protein was been able to recognized by anti-EGF antibodies. Further, there was increase in the EGF concentration, where 2 copies of EGF introduced in the chimeric construct
sequence (E2FS1). Table 4, as given below, shows the theoretical equimolar ratios of EGF & FliC or SDM in each chimeric construct and the estimated EGF concentration by EFISA. Figure 3A illustrates the estimated EGF concentration reflects antigenicity or epitopes exposed, but not the protein concentration.
Table 4: Theoretical equimolar ratios of EGF & FliC or SDM in each chimeric construct and the estimated EGF concentration by EFISA.
Example 4.2: Relative estimation of Full Length or truncated Flagellin by ELISA: To assess, the relative amount of flagellin epitopes exposed in chimeric proteins, 96 well plate was coated with 100 pi of each protein at equal concentration (1 pg/ml), diluted in PBS, pH 7.4. Plate was incubated for overnight at 4C. Subsequently 3 washes with PBST were carried out and then the plates were blocked with a solution of 1 x PBS containing 0.5% skim milk, incubated them during a period of 1 hour at RT. Next step, the plates were incubated with 50 ul/well of anti-mouse-FliC antibody HRP conjugate (1:5000 dilution) for 1 hour at RT. Reaction color was developed with TMB 50 ul/well, incubated for 30 minutes at RT. Optical density was measured at 450 nm in an ELISA plate reader.
The results were demonstrated the activity and the efficiency of the chimeric proteins, as these proteins maintain EGF recognition sites for the capture anti-EGF antibody. It also demonstrated that there is an increase in the concentration of EGF, as the number of EGF copies increase, further, FliC or SDM used as carrier protein in these chimeric proteins were
also recognized by the anti-FliC antibodies, as demonstrated by antibody capture assay (ELISA). Furthermore, these results showed that EGFL and E2FS1 elicited less anti-FliC compared to E1FS1, as illustrated in Figure 3 A.
Example 4.3: Adjuvant activity of FliC or SDM in chimeric constructs: Flagellin has the ability to bind to TLR5 receptors that are present on the surface of the immune cells, so as to stimulate immune response. TLR5 (Toll Like Receptor 5) receptor is an (extracellular) pattern recognition receptor (PRRs) recognizes D1 domain of flagellin and stimulates cascade of signalling pathways to induce immune response. To demonstrate whether the generated chimeric fusion proteins in the present invention stimulate TLR5 receptor or not, we stimulated TLR5 reporter cell lines (i.e HEK-Blue Human TLR5 reporter cell lines) with chimeric fusion proteins of the present invention described in the following section
Example-4.3a: Cell lines and treatments: HEK - Blue Human TLR5 reporter cell lines purchased from Invivogen, California, USA. These cells were prepared by co-transfection of human TLR5 gene and codon-optimized SEAP (secreted embryonic alkaline phosphatase) as a reporter gene into HEK 293 cells. Cell lines were cultured in DMEM, 4.5 g/1 glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 pg/ml streptomycin, 100 pg/ml Normocin™. Upon stimulation of cells with chimeric fusion proteins containing full length or truncated flagellin, NFkB gets activated, which in-tum secrets SEAP and it was measured in cell supernatant using spectrophotometer at wavelength 630-650 nm.
Example-4.3b: TLR5 Specific Reporter Assay: HEK - Blue Human TLR5 reporter cells (5xl04 / well) were plated and cultured overnight in a humidified CO2 incubator at 37°C. Next day, cells were treated with various concentrations of chimeric fusion protein/s, (0.0001 to 1000 ng/ml) and cultured for 16 hours. Cells were also treated with Flagellin (FliC) or truncated flagellin (SDM) as a positive control. EGF was also tested for TLR5 activity, but EGF didn’t show any activity (hence results not shown). Supernatant was collected and treated with Quanti blue detection reagent at 37°C for 15-30 minutes. Absorbance was read at 630 nm. Dose response curve was generated by plotting concentration of protein on X-axis and % response on the Y-axis is as shown in Figure 4A and Figure 4B. To generate dose response curve, highest absorbance shown at tested concentration was taken as 100% response and the least absorbance was taken as 0% response. Effective concentration at 50% (EC50) response was determined from the dose response curve.
In the present invention, proteins showed maximum 100% response with a high absorbance at 1000 ng/ml concentration (reached plateau at this concentration in sigmoidal curve), whereas, 0% response with a low absorbance at 0.0001 ng/ml concentration. These results indicated EC so as 3.5, 0.006, 0.01, 0.99 & 0.08 ng/ml of EGFL, E1FS1, E2FS1, FliC & SDM respectively (concentration at which protein(s) showed half maximal response).
In conclusion, the results obtained indicated that the chimeric fusion proteins EGFF / E1FS1/ E2FS1 of the present invention were able to stimulate immune cells that express TFR5 receptors, which in-tum determines its ability to enhance immune response and thereby has the capacity to act as an adjuvant as a whole for elevated immune responses, as illustrated in Figure 4A and Figure 4B .
Example 4.3c: Anti-tumorigenic Property Assay {In-Vitro)’. Usually, activated macrophages or immune cells that express TFR5, secretes IF-8, which in-tum induces physiological responses that lead to the recruitment of granulocytes, neutrophils at the site of infection or it leads to phagocytosis or chemotaxis. Secretion of IF-8 is also a measure of anti-tumorigenic property. In the present invention, to confirm IF-8 secreted by activated immune cells with TFR5 was measured by EFISA, which in-turn signifies the anti- tumorigenic property of the chimeric fusion proteins of the present invention as disclosed in Example 4C above. To estimate IF-8, supernatant collected from stimulated HEK Blue reporter cells with chimeric protein(s) or flagellin was used and performed EFISA as disclosed in the below sections^
Example 4.3d: Determination of IL-8 by ELISA: To quantify human Interleukin 8 (hu IF- 8) in cell culture supernatant, Enzyme Finked Immunosorbent Assay (EFISA) kit purchased from Thermo scientific (Cat#EH2IF8) was used. All reagents, standards, samples were prepared as per the instruction manual. A series of 2.5fold dilutions of standard ranging from (0, 25.6, 64, 160, 400 & 1000 pg/ml) and similarly, 4-fold dilutions (1:4, 1:16 & 1:64) of cell supernatant were prepared to quantitate IF-8 concentration secreted by cells after TFR5 stimulation. Briefly, anti-huIF-8 pre-coated 96 well strip plate was used and to this, 50 pL standard or samples were added to each well. The plate was incubated at room temperature for 1 hour and washed the plate thrice. Eater, 50 pF/well of biotinylated antibody diluted as per manual instructions was added to each well and incubated at room temperature for 1 hour.
Later, 100 pL of streptavidin-HRP was added to each well and incubated at room temperature for 30 minutes. Finally, after washes, 100 pL of TMB solution was added to each well and incubated at RT for 15 minutes. Reaction was stopped by the addition of 100 pL of stop solution to each well and the plate was read at 450 nm. Figure 3 represents, bar graph of IL-8 cytokine levels secreted by chimeric protein and FliC (as a positive control).
Example 4.4: Anti-Cell Proliferation Assay: Several antitumor therapies target the EGFR pathway as a way of treatment. However, the use of tyrosine kinase inhibitors (TKIs) namely Geftininb or Erlotinib etc., are one among are the standard treatment in advanced NSCLC with EGFR mutations (Rosell R, et ah, 2012; Maemondo M, et ah, 2010). To know the effect on mechanism of action of mouse anti-EGF antibodies raised against recombinant chimeric proteins (EGFL or E1FS1 or E2FS1 or BsE2FSl or E1FS2 or E2FS2 or EGFL2), EGFR mutant NSCLC cell lines (NCI-H1975, ATCC, lOxlO3 cells or PC 9 Cells, ATCC, 3xl03 cells) were treated and analyzed for anti-cell proliferation. Cell growth and viability is assessed by MTT assay. As the EGF is considered to boost the cell proliferation in cancer cells, this experiment is conducted to analyse the anti-proliferative effect of sera raised against chimeric proteins in the presence of EGF on human lung cancer cell line.
Anti-proliferative activity of Most known TKIs:
In-Vitro Assay: Lung Cancer Cells (NCI-H1975, ATCC, lOxlO3 cells or PC9 Cells, ATCC, 3xl03 cells) were seeded in 96 well plate using RPMI 1640 complete media (10% FBS and 1% PenStrep), allowed to attach for 24 hours at 37°C in 5% CO2 incubator. Media was discarded and treated with EGF or mouse anti-sera raised against recombinant chimeric proteins (EGFL or E1FS1 or E2FS1 or BsE2FSl or E1FS2 or E2FS2) or EGFR TKIs (Gefitinib at IC50 - Inhibitory concentration that causes 50% deaths) either individually or in combinations for 72 hours in RPMI 1640 media without FBS. Mouse unvaccinated sera and anti-sera raised against recombinant proteins (EGF or FliC or SDM) were used as controls. After 72 hours of treatment, supernatant was discarded and cells were incubated with 100 pis of MTT (Thiazolyl Blue Tetrazolium Bromide) Reagent at a concentration of 10 mg/ml for 2- 3 hours incubation at 37°C. Plate was observed for formazan crystals and MTT reagent was removed. Crystals were dissolved in 50 pis of DMSO and read at 540 nm. This assay revealed that the vaccinated sera raised against recombinant chimeric proteins were able to suppress the stimulating effects of human EGF (hEGF) on cell proliferation, whereas unvaccinated sera had no effect on cell proliferation. Further, combination treatment of Geftinib along with
vaccinated sera raised against chimeric proteins shown more anti-cell proliferation effect compared to cells that are treated with either vaccinated sera alone or with Geftinib treatment alone at IC50 (Figure 5A and Figure 5B). The results of Anti-Proliferation Assay have been shown in Tables 5 and 6.
TABLE 5: Anti-Proliferation Assay
TABLE 6: Anti-Proliferation Assay along with Geftinib
Example 5: Evaluation of mice immune response by the Immunotherapeutic vaccine candidates comprising human epidermal growth factor
In order to demonstrate whether recombinant chimeric proteins (EGFL or E1FS1 or E2FS1) are able to elicit antibodies against huEGF, vaccination study was performed in C57BL/6 mice.
Immune response of mice against recombinant chimeric proteins:
Example 5.1: Immunization: C57BL/6 mice (4-8week old, female) mice were purchased and maintained in the animal care facility under standard approved protocols. All procedures involving mice were carried out with the approval of Institutional Animal Ethics Committee. For this, C57BL/C mice (6-8 week old, female, n=6) were injected intra-muscularly with chimeric proteins (EGFL or E1FS1 or E2FS1, 50 pg/mouse/100 pi) on day 0, 14 and 28. Mice were bled one day before each immunization and 14 days after last immunization. Sera was separated from blood and used to evaluate the total anti-EGF/anti-FliC antibody titer & its antibody isotypes (IgGi, IgG2a or IgGi) by ELISA. In this experiment, control group of mice were also injected with EGF or FliC or SDM. Group of mice, received EGF were tested at three different concentrations (5, 10 & 16 pg/mouse/100 pi), which is equivalent to 50 pg of EGFL, E1FS1 & E2FS1 respectively. These equivalent EGF concentrations generated based on the equimolar ratio of EGF & FliC or SDM from chimeric proteins. It was established that chimeric proteins elicited high titer anti-EGF antibodies. Anti-EGF antibody titer elicited by EGFL (25 pg/mouse) in mice is represented as in Figure 6A. End point titer representing anti- EGF specific antibody raised against chimeric proteins EGFL, E1FS1, and E2FS1 and are depicted in Figure 6B, Figure 6C and Figure 6D respectively.
Vaccine formulation: Chimeric protein (50pg/mouse of EGFL or E1FS1 or E2FS1) in Phosphate buffered saline, pH 7.4 with 5-40% trehalose mixed with aluminium hydroxide in 1 : 1 ratio with a recommended aluminium content.
Anti-EGF End Point Titer: Pooled serum samples were used to determine anti-EGF antibody titer. To perform ELISA, 96 well microtiter plates were coated with huEGF at a concentration [1 or 10 pg/ml, 100 pl/well either in PBS or carbonate buffer (15 mM Na2C03, 35 mM NaHC03, pH 9.6)] and kept at 4°C for overnight. Next day, plates were washed with washing buffer (PBST) and blocked with blocking buffer (PBS with 1% BSA) at RT for 1-2 hour ELISA plates were washed again with wash buffer (PBS, 0.1% Tween™20) and added serially diluted (dilutions from 1;50 to 819200 in PBS, 0.1% BSA, 0.05% Tween™20, 0.02% sodium azide) sera from hyper immunized mice and incubated at RT for 1 hour. After one hour incubation, wells were washed and added Goat Anti- mouse IgG HRP conjugate antibody (dilution 1:5000) and kept for 1 hour incubation at RT. After incubation, wells were washed, and developed with TMB as a substrate. Absorbance was read at 450 nm. Threshold (Mean + 3SD) was established by taking the absorbance of negative control (PBS) group. Anti-EGF end point titers were determined after considering the threshold value.
End point titer representing anti-EGF antibody elicited against chimeric proteins EGFL, E1FS1, and E2FS1 and are depicted in Figure 7A, Figure 7B and Figure 7C respectively. These results demonstrated that EGFL and E2FS1 elicits lesser anti-FliC antibodies as compared to E1FS1.
Anti-FliC End Point Titer: Pooled serum samples were used to determine background elicited against full length or truncated flagellin. To perform this, 96 well microtiter plates were coated with FliC at a concentration [1 or 10 pg/ml, 100 pl/well either in PBS or carbonate buffer (15 mM Na2C03, 35 mM NaHC03, pH 9.6)] and kept at 4°C for overnight. Next day, plates were washed with washing buffer (PBST) and blocked with blocking buffer (PBS with 1% BSA) at RT for 1-2 hour. ELISA plates were washed again with wash buffer (PBS, 0.1% Tween™20) and added 4-fold serial dilutions (in PBS, 0.1% BSA, 0.05% Tween™20, 0.02% sodium azide) of hyper immunized sera (1;50 to 819200) and incubated at RT for 1 hour. After one hour incubation, wells were washed and added Goat Anti-mouse IgG HRP conjugate (dilution 1:5000) antibody and kept for 1 hour incubation at RT. After incubation, wells were washed, and developed with TMB as a substrate. Absorbance was read at 450 nm. Threshold (Mean + 3SD) was established by taking the absorbance of negative control (PBS) group. Anti-FliC end point titers were determined after considering the threshold value.
IgG sub class (Isotype) determination: In order to demonstrate, the type of IgG subclass, pooled mice hyper immunized serum samples were used to perform ELISA. Microtiter (96 well) plates were coated with huEGF at a concentration [1 or lOpg/ml, IOOmI/well either in PBS or carbonate buffer (15 mM Na2C03, 35 mM NaHC03, pH 9.6)] and kept at 4°C for overnight. Next day, plates were washed with washing buffer (PBST) and blocked with blocking buffer (PBS with 1% BSA) at RT for 1-2 hour. ELISA plates were washed again with wash buffer (PBS, 0.1% Tween™20) and added serially diluted (in PBS, 0.1% BSA, 0.05% Tween™20, 0.02% sodium azide) sera from hyper immunized mice and incubated at RT for 1 hour. After one hour incubation, wells were washed and appropriate dilutions of anti mouse IgG isotype subclass antibodies (IgGi or IgG2a or IgG3) were added for incubation at RT. Wells were washed and incubated 1 hour with Goat Anti- mouse IgG HRP conjugate secondary antibody. After incubation, wells were washed, and developed with TMB as a substrate. Absorbance was read at 450 nm. Threshold (Mean + 3SD) value was established by taking the absorbance of negative control (PBS) group. Thi/Th2 index was calculated using the formula as [IgG2a+IgG3)/2]/[(IgGi). This assay demonstrated that all chimeric proteins biased towards Th2 responses, as indicated by Thi/Th2 index, which was <1, which is illustrated in Figure 6E.
Example 6: Immunogenicity of chimeric proteins in combination with adjuvant/s:
The term "adjuvant" as used herein refers to a specific stimulator of the immune cells which when combined with the chimeric vaccine antigens of the present invention provides an even more enhanced antigen specific immune response. In this illustrative embodiment,, to enhance the immune response of chimeric protein(s), apart from the presence of flagellin in the chimeric vaccine antigen, various adjuvants (aluminum hydroxide and MDP, GMDP and their derivatives, MPL, poly (I:C), CpG etc.,) were co-administered with the chimeric vaccine antigens either alone or in combination with delivery system (emulsions Oil in Water or Water in Oil etc.,) or combination of one or more of the adjuvants.
Vaccination: To demonstrate enhanced immune response in the presence of adjuvants, C57BL/C mice (6-8week old, female, n=6) were injected intra-muscularly either with chimeric proteins (EGFL or E1FS1 or E2FS1, 50pg/mouse) alone or in combination with aluminium hydroxide (1:1) on day 0 and 14. Blood was collected on day 28 and separated serum for further antibody titer analysis by ELISA as mentioned in example 5.1. These results
indicated that anti-EGF antibody titers were further enhanced in the presence of adjuvants as an additional component of the vaccine composition comprising the chimeric proteins of the present invention. EGF specific antibody titers obtained when chimeric protein EGFL or E1FS1 and E2FS1 tested in combination with alum are represented in Figure 8A, Figure 8B and Figure 8C respectively.
Example 7: Therapeutic Vaccination in Tumor Induced Mice Model:
The main objective of this experimental procedure was to demonstrate that the chimeric proteins comprising autologous huEGF are able to show antitumor effect against EGF dependent tumors. To conduct therapeutic vaccination against chimeric proteins, tumor induced mice model (syngeneic model) was used and the protocol is as mentioned below.
Example 7.1 Cell lines: FECI (Fewis Fung Carcinoma 1) cell lines were obtained from the American Type Culture Collection (ATCC Cat# CRF-1642). FECI cells were cultured in DMEM medium (Invitrogen). Medium was supplemented with 10% fetal bovine serum (Invitrogen), 100 IU/mF of penicillin, and 100 pg/mF of streptomycin (Invitrogen) and cells grown at 37°C in a humidified incubator containing 5% CO2. C57BF/6 mice (5-6 week old, female, n=15) were injected with 0.2 x 106 or 1 x 106 FECI cells/0.2 ml PBS, on day 0 via subcutaneous route (s.c). Simultaneously, control group mice (n=10) were also injected with PBS and maintained. Body weight and tumor size were measured twice a week using weighing balance and vernier callipers, respectively. Tumor volume was calculated using the formula w2xl2 where w = width and l = length. Mice developed tumor from day 7 onwards. Mice that received lxlO6 cells/mouse, shown rapid tumor development, whereas mice that received 0.2xl06 cells/mouse have shown slow tumor growth (Figure 9). Hence, high cell density (lxlO6 cells/ mouse) was selected to generate mice induced tumor model, for therapeutic vaccination study by chimeric proteins comprised of EGF.
Example 7.2 Therapeutic Vaccination against EGFL: C57BF/6 mice were injected with FECI (lxl06/0.2ml) cells resuspended in PBS, on day 0 via subcutaneous route (s.c). Tumor volume was measured and mice bearing tumor size ranging less than 2 cm were selected for therapeutic vaccination study. Further, these tumor induced C57BF/6 mice were randomized into four groups (n=15), based on the tumor size. First group (i.e tumor induced, untreated, n=15) of mice were used as controls, to compare the survival rate. Other three groups of
mice were treated with 3 doses of EGFL or EGF or FliC, at an interval of 14 days, starting on day 10. Second group (i.e tumor induced, treated, n=15) of mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of EGFF. Third group of mice received EGF at 5 pg/mouse, which is of equivalent to EGF concentration in EGFL, interms of equimolar ratio. Fourth group of mice received FliC at 50 pg/mouse. EGF & FliC were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
Mice treated with EGFL showed approximately 20% survival benefit compared to untreated mice (mice received cells alone) as shown in Figure 11 A, which is statistically significant (p value = 0.02), according to Log rank (Mantel Cox), with Hazard Ratio 2.84. Mice received EGF & FliC didn’t show significant survival benefit showing Hazard Ratio (mentioned in Figures as HR) of 0.93 and 1.0 respectively, as shown in Figures 11D and 11E respectively.
Example 7.3 Therapeutic Vaccination against E1FS1: C57BL/6 mice were injected with LLC1 (lxl06/0.2ml) cells resuspended in PBS, on day 0 via subcutaneous route (s.c). Tumor volume was measured and mice bearing tumor size ranging less than 2 cm were selected for therapeutic vaccination study. Further, these tumor induced C57BL/6 mice were randomized into four groups (n=15), based on the tumor size. First group (i.e tumor induced, untreated, n=15) of mice were used as controls, to compare the survival rate. Other three groups of mice were treated with 3 doses of E1FS1 or EGF or SDM, at an interval of 14 days, starting on day 10. Second group (i.e tumor induced, treated, n=15) of mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of E1FS1. Third group of mice received EGF at 10 pg/mouse, which is of equivalent to EGF concentration in E1FS1, interms of equimolar ratio. Fourth group of mice received SDM at 50 pg/mouse. EGF & SDM were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
Mice treated with E1FS 1 showed 20 % survival benefit, compared to untreated mice (mice received cells alone), which is statistically significant, according to Log rank (Mantel Cox)
test with a p value 0.01) and showed, Hazard ratio 2.3 as shown in Figure 11B. Mice received EGF & SDM didn’t show significant survival benefit showing Hazard Ratio of 0.93 and 0.63 respectively as shown in Figure 11D and Figure 11 F respectively.
Example 7.4 Therapeutic Vaccination against E2FS1: C57BL/6 mice were injected with LLC1 (lxl06/0.2ml) cells resuspended in PBS, on day 0 via subcutaneous route (s.c). Tumor volume was measured and mice bearing tumor size ranging less than 2cm were selected for therapeutic vaccination study. Further, these tumor induced C57BL/6 mice were randomized into four groups (n=15), based on the tumor size. First group (i.e tumor induced, untreated, n=15) of mice were used as controls, to compare the survival rate. Other three groups of mice were treated with 3 doses of E2FS1 or EGF or SDM, at an interval of 14 days, starting on day 10. Second group (i.e tumor induced, treated, n=15) of mice were treated with immunotherapeutic vaccine candidate 50 pg/mouse of E2FS1. Third group of mice received EGF at 16 pg/mouse, which is of equivalent to EGF concentration in E2FS1, interms of equimolar ratio. Fourth group of mice received SDM at 50 pg/mouse. EGF & SDM were tested as controls in third & fourth group respectively, as these two proteins are part of chimeric protein, a therapeutic vaccine candidate. Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality. Survival rate was determined among groups.
Mice treated with E2FS 1 showed approximately 20% survival benefit, compared to untreated mice (mice received cells alone), showed Hazard ratio of 2.2 as shown in Figure 11C.
Example 7.5 Therapeutic Vaccination via Combination therapy: To demonstrate, the efficacy these chimeric proteins in tumor induced mice, after targeted therapy treatment or while undergoing targeted therapy treatment, tumor induced mice were generated and randomized into three groups (n=15 each) as in Example 7.2. One group (i.e untreated, n=15) of tumor induced mice were used as controls, to compare the survival rate. Remaining groups were treated either with targeted therapy (Gefitinib treatment) or therapeutic vaccination (with chimeric proteins, EGFL or E1FS1 or E2FS1) or in combination (Gefitinib treatment followed by therapeutic vaccination with EGFL or E1FS1 or E2FS1). In the present invention, gefitinib (Gef, 2.5 mg/mouse/dose) treatment was administered on day 5 for up to 3-4 weeks (5 days/week). Therapeutic vaccination was given with EGFL or E1FS1 or E2FS1 (50 pg/mouse/dose) on day 7 or 9, followed by 3 vaccinations at an interval of 14 days (i.e at
day 7, 21, 35 & 49). Mice treated with combination therapy received both targeted therapy for 3-4 weeks along with 3 doses of EGFL or E1FS1 or E2FS1 (50 pg/mouse/dose) vaccination. Body weight and tumor size were measured twice a week using weighing balance and vernier callipers, respectively. Though the tumor size started to grow drastically across all mice that received LLC1 cells from Day 7 to day 17, thereafter there was a slow growth in treated mice that received either targeted therapy or immunotherapy or combinational therapy. Further, significant slow growth was observed in mice which received combination therapy compared to tumor induced mice (untreated mice) (Figure 10A).
Mice were also observed daily for any abnormal behavioural patterns, clinical signs and mortality & mice survival rate was determined among groups. Combination of Targeted therapy & immunotherapy showed better survival rate. EGFF protein survived for longer period showing 20% more survival benefit compared to mice received FECI cells alone as shown in Figure 11 A. Further, mice received combination therapy, i.e. Geftinib treatment followed by EGFF treatment showed 50% survival benefit as compared to Geftinib alone with a hazard raio 2.3, as shown in Figure 12A and Figure 12B. The order of survival rate EGFF+Gef (50%) > Gef (19%) > EGFF > FECI. Similar results were found for the E1FS1 and E2FS1 chimeric proteins. In conclusion, these results demonstrated that EGF based Chimeric fusions proteins are in synergy with targeted therapy.
Example 7.6 Anti-EGF titer determination after therapeutic Vaccination: Mice were bled at one day before each vaccination from all groups (both treated, untreated and other control groups), as mentioned in examples 7.2 to 7.5. Serum was collected from blood and used to estimate mouse EGF levels and mouse anti-EGF antibodies by EFISA as given in Example 5.1 and 7.7. Vaccinated groups either individually or combination with Gefitinib induced high anti-EGF antibodies. Mice received combination therapy clearly showed an inverse relation between anti-EGF antibody titer and EGF levels (Figure 10B) estimated in the treated mice (either drug alone or fusion protein or combination therapy), which in turn benefited with increased survival rate (Figure 12A and Figure 12B).
Example 7.7 Murine EGF Quantitation: To evaluate the correlation between the EGF levels and anti-EGF immune response in blood, serum was separated from blood, EGF levels were estimated in both treated & untreated groups using individual mouse sera. To quantify mouse EGF levels, Mouse EGF quantikine EFISA kit (Cat#MEG00) or DY2028 was
purchased from R&D systems. All reagents, standard dilutions, Controls and samples were prepared as per the instruction manual. Pre-coated microtiter strips were used to perform ELISA. Serial dilutions of standard or samples prepared as per instructions were added to each well (IOOmI/well) and incubated plate for 2hrs at RT. After five washes with washing buffer, 100 pL of Mouse EGF Conjugate was added to each well and incubated plate for 2hrs at RT. After washing the plate, Substrate Solution 100 pL was added to each well and incubated for 30 minutes at room temperature. Finally, reaction was stopped by the addition of stop solution. Optical density was measured at wavelength 450nm and subtracted these readings from 540 or 570nm. Standard graph was plotted by taking EGF standard concentrations on X-axis and optical density on the Y-axis. EGF levels in samples were also calculated by using the regression equation. Figure 12A and Figure 12B showed that combination of targeted therapy & immunotherapy showed better survival rate.
References:
1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation positive non small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small- cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
3. Sang Hoon Rhee, Eunok IM, and Charalabos Pothoulakis; Toll-Like Receptor 5 Engagement Modulates Tumor Development and Growth in a Mouse Xenograft Model of Human Colon Cancer. Gastroenterology 2008, 135:518-528.
4. Li Fen Lee, Ronald P Hellendall, Ying Wang, J. Stephen Haskill, Naofumi Mukaida, Kauji Matsushima, Jenny Y-P Ting (2000). IL-8 reduced tumorigenicity of human Ovarian cancer In Vivo due to neutrophil infiltration. J Immunol 2000; 164:2769- 2775.
Claims
1. A vaccine composition for immunotherapy against cancer, comprising:
a. vaccine antigen, the said vaccine antigen is a chimeric protein or construct;
b. adjuvants;
c. stabilizers; and
d. a physiologically acceptable buffer selected from phosphate and citrate.
2. The vaccine composition as claimed in claim 1, wherein the vaccine antigen comprising one or more of the chimeric protein sequences as represented by SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2).
3. The vaccine composition as claimed in claim 2, wherein the chimeric protein is obtained from a codon optimized gene sequences comprising one or more of as represented by SEQ ID No. 1. (EGFL), SEQ ID No. 2 (E1FS1), SEQ ID No. 3 (E1FS2), SEQ ID No. 4 (E2FS1), SEQ ID No. 5 (E2FS2), SEQ ID No. 11 (BsE2FSl) or SEQ ID No. 12 (EGFL2).
4. The vaccine composition as claimed in claim 2, wherein the chimeric protein comprises of growth factor linked to N-terminal or C-terminal or middle of the full length or truncated carrier protein and is genetically synthesized.
5. The vaccine composition as claimed in claim 2, wherein the chimeric protein is expressed in prokaryotic expression system through a prokaryotic expression plasmid.
6. The vaccine composition as claimed in claim 4, wherein the growth factor is human EGF.
7. The vaccine composition as claimed in claim 6, wherein the human EGF epitopes are exposed on the surface of the chimeric proteins.
8. The vaccine composition as claimed in claim 4, wherein the carrier protein is a genetically synthesized full length Flagellin protein.
9. The vaccine composition as claimed in claim 4, wherein the carrier protein is a genetically synthesized truncated Flagellin protein without the hypervariable region that are from amino acid number 178 to amino acid number 405 or from amino acid number 186 to amino acid number 285.
10. The vaccine composition as claimed in claim 8 or 9, wherein the genetically synthesized sequence is selected from Gram positive bacteria including without limitation to Bacillus subtilis, Clostridium difficile, g— protcobactcria such as Salmonella typhimurium, Enterica species or b-proteobacteria such as Bordetella.
11. The vaccine composition as claimed in claim 8 or 9, wherein the carrier protein helps the immune system to recognize autologous EGF to induces immune response against EGF, and acts as adjuvant to enhance Th2 responses or B cell mediated immune responses.
12. The vaccine composition as claimed in claim 1, wherein the adjuvant is selected for a group comprising one or more of a group of aluminium salts such as aluminium phosphate or aluminium hydroxide, squalene based adjuvants such as MF59, montanide, RIBI adjuvant, incomplete Freund's, glucans, oil-in-water emulsion, MPL, muramyl dipeptide, muramyl dipeptide derivatives, agonists of TLRs (TLR1 to TLR 13) such as MPL, MDP, Imiquimod, poly (I:C), CpG oligonucleotides, Non-CpG oligonucleotides, saponins such as QS-1, ISCOM, ISCOMATRIX, vitamins or immunomodulants such as cytokines, IL-12, IL-15 etc.
13. The vaccine composition as claimed in claim 1, wherein the stabilizers comprises one or more of sugars such as 5-40% Trehalose or sugar alcohols such as 5-40% Glycerol or 5-40% Sorbitol.
14. The vaccine composition as claimed in claim 2, wherein the said vaccine antigens of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID
No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) are expressed in E.Coli using the pTWINl plasmid and purified proteins by self-cleavage, by temperature from 50-65°C and pH shift ranges from pH 6.5 to 7.5.
15. A method of isolation and purification of proteins of SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl), SEQ ID No. 17 (EGFL2), SEQ ID No. 18 (FliC), SEQ ID No. 19 (SDM) or SEQ ID 20 (EGF) comprising the following steps: i. introducing the recombinant expression plasmid into bacterial host cells in high cell density growth media;
ii. isolation of protein either in the form of insoluble protein from inclusion bodies or in the form of soluble protein;
iii. purification of chimeric proteins by at least one or two of the following methods: ion exchange chromatography, size exclusion chromatography, affinity chromatography or hydrophobic interaction column chromatography.
16. The vaccine composition as claimed in claim 2, wherein each of the chimeric protein sequence as disclosed in SEQ ID No. 6. (EGFL), SEQ ID No. 7 (E1FS1), SEQ ID No. 8 (E1FS2), SEQ ID No. 9 (E2FS1), SEQ ID No. 10 (E2FS2), SEQ ID No. 16 (BsE2FSl) or SEQ ID No. 17 (EGFL2) are at least 90% - 99% pure.
17. A method of treatment to regulate the tumor growth or to increase the survival rate, comprising therapeutic vaccine composition with or without Tyrosine Kinase Inhibitors (TKIs).
18. The method as claimed in claim 17, wherein the Tyrosine Kinase Inhibitors is comprising 1st or 2nd or 3rd generation TKIs such as Geftinib, Erlotininb, Afatinib, Dacomitinib, Avitinib, Olmutinib, Nazartinib.
19. The method as claimed in claim 15, wherein the high cell density growth media comprises 1.5% yeast extract, 1.5% Casein, 0.4% glycerol, M9 salt solution, trace elements, 1M MgS04, 1M CaCh, Biotin, Thiamine and ampicillin.
20. The vaccine composition as claimed in claim 1, wherein the said composition is stable for at least 2 years at 2-8°C and up to 2 weeks at 37°C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841020522 | 2018-11-30 | ||
IN201841020522 | 2018-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020110154A1 true WO2020110154A1 (en) | 2020-06-04 |
Family
ID=70852273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2019/050877 WO2020110154A1 (en) | 2018-11-30 | 2019-11-30 | A chimeric therapeutic vaccine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020110154A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021259397A3 (en) * | 2020-06-09 | 2022-04-14 | Centro De Inmunología Molecular | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
CN116143938A (en) * | 2021-02-04 | 2023-05-23 | 广东珩达生物医药科技有限公司 | COVID-19 subunit vaccine and preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053219A2 (en) * | 1999-03-11 | 2000-09-14 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
WO2006039701A1 (en) * | 2004-10-01 | 2006-04-13 | University Of South Florida | Flagellin-based adjuvants and vaccines |
WO2006081007A2 (en) * | 2004-12-16 | 2006-08-03 | Wake Forest University Health Sciences | Use of flagellin in tumor immunotherapy |
WO2008109757A2 (en) * | 2007-03-06 | 2008-09-12 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
WO2010037514A2 (en) * | 2008-10-01 | 2010-04-08 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
CN107073092A (en) * | 2014-07-30 | 2017-08-18 | 克利夫兰生物实验室公司 | Agent based on flagellin and the purposes including being effectively inoculated with |
-
2019
- 2019-11-30 WO PCT/IN2019/050877 patent/WO2020110154A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053219A2 (en) * | 1999-03-11 | 2000-09-14 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
WO2006039701A1 (en) * | 2004-10-01 | 2006-04-13 | University Of South Florida | Flagellin-based adjuvants and vaccines |
WO2006081007A2 (en) * | 2004-12-16 | 2006-08-03 | Wake Forest University Health Sciences | Use of flagellin in tumor immunotherapy |
WO2008109757A2 (en) * | 2007-03-06 | 2008-09-12 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
WO2010037514A2 (en) * | 2008-10-01 | 2010-04-08 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
CN107073092A (en) * | 2014-07-30 | 2017-08-18 | 克利夫兰生物实验室公司 | Agent based on flagellin and the purposes including being effectively inoculated with |
Non-Patent Citations (3)
Title |
---|
ASADI-GHALEHNI ET AL.: "A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model", MICROBIOLOGY AND IMMUNOLOGY, vol. 61, no. 12, 16 November 2017 (2017-11-16), pages 531 - 538, XP055712748 * |
HAJAM ET AL.: "Bacterial flagellin-a potent immunomodulatory agent", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 9, 1 September 2017 (2017-09-01), pages e373, XP055465854, DOI: 10.1038/emm.2017.172 * |
SFONDRINI ET AL.: "Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 11, 1 June 2006 (2006-06-01), pages 6624 - 6630, XP055712746 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021259397A3 (en) * | 2020-06-09 | 2022-04-14 | Centro De Inmunología Molecular | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
CN116143938A (en) * | 2021-02-04 | 2023-05-23 | 广东珩达生物医药科技有限公司 | COVID-19 subunit vaccine and preparation method and application thereof |
CN116143938B (en) * | 2021-02-04 | 2023-11-10 | 广东克冠达医药科技有限公司 | COVID-19 subunit vaccine and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7470669B2 (en) | Recombinant proteins and their therapeutic uses | |
AU2017258877B2 (en) | Dna vaccine for use in pancreatic cancer patients | |
Disis et al. | Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein—based vaccine | |
JP5222134B2 (en) | HER-2 peptide | |
TW201622743A (en) | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof | |
JP7072921B2 (en) | Group A streptococcal vaccine | |
Mori et al. | Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori | |
WO2020110154A1 (en) | A chimeric therapeutic vaccine | |
KR101810840B1 (en) | Msi-specific framshift peptides (fsp) for prevention and treatment of cancer | |
WO2016168198A1 (en) | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same | |
BR112020001045A2 (en) | synthetic proteins and therapeutic uses thereof | |
CN112203681A (en) | Vaccine composition and use thereof | |
KR102372615B1 (en) | Vaccine compositions and uses thereof | |
AU2006228872A1 (en) | Immunogenic EGFR peptides comprising foreign Tcell stimulating epitope | |
RU2607379C2 (en) | Cancer antigen | |
KR100834383B1 (en) | Vaccine composition containing transforming growth factor alpha | |
Atzingen et al. | Induction of boosted immune response in mice by leptospiral surface proteins expressed in fusion with DnaK | |
JP5890769B2 (en) | MSI-specific frameshift peptides (FSP) for cancer prevention and treatment | |
JP2003521523A (en) | Methods for preventing or attenuating pathological neovascular conditions | |
RU2775621C2 (en) | Immunogen peptide against group a streptococci | |
EP4082562A2 (en) | Polypeptides comprising mutated forms of human vegf-a with rearrangements of disulfide bonds and compositions containing same | |
Mulet et al. | The enlargement of the hormone immune deprivation concept to the blocking of TGFα-autocrine loop: EGFR signaling inhibition | |
US20030082201A1 (en) | Multivalent synthetic vaccine for cancer | |
TW202246305A (en) | Recombinant protein of flagellin and use thereof enhancing the humoral immunity and the cellular immunity of the chicken against the antigen and the protective effect of the vaccine | |
KR20220058527A (en) | Stabilized chimeric synthetic protein and its therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19890982 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19890982 Country of ref document: EP Kind code of ref document: A1 |